US20170159016A9 - Selective differentiation, identification, and modulation of human th17 cells - Google Patents
Selective differentiation, identification, and modulation of human th17 cells Download PDFInfo
- Publication number
- US20170159016A9 US20170159016A9 US14/517,116 US201414517116A US2017159016A9 US 20170159016 A9 US20170159016 A9 US 20170159016A9 US 201414517116 A US201414517116 A US 201414517116A US 2017159016 A9 US2017159016 A9 US 2017159016A9
- Authority
- US
- United States
- Prior art keywords
- cells
- tgf
- cell
- human
- differentiation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000282414 Homo sapiens Species 0.000 title abstract description 59
- 230000004069 differentiation Effects 0.000 title abstract description 46
- 210000000068 Th17 cell Anatomy 0.000 claims abstract description 134
- 230000000694 effects Effects 0.000 claims abstract description 46
- 102100033374 Leukotriene B4 receptor 1 Human genes 0.000 claims abstract description 39
- 101100236208 Homo sapiens LTB4R gene Proteins 0.000 claims abstract description 35
- 101100437750 Schizosaccharomyces pombe (strain 972 / ATCC 24843) blt1 gene Proteins 0.000 claims abstract description 35
- 102100037265 Podoplanin Human genes 0.000 claims abstract description 33
- 101710118150 Podoplanin Proteins 0.000 claims abstract description 33
- 239000005557 antagonist Substances 0.000 claims abstract description 33
- 210000004027 cell Anatomy 0.000 claims description 70
- 238000000034 method Methods 0.000 claims description 47
- 102000004887 Transforming Growth Factor beta Human genes 0.000 abstract description 116
- 108090001012 Transforming Growth Factor beta Proteins 0.000 abstract description 116
- 108010074108 interleukin-21 Proteins 0.000 abstract description 112
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 abstract description 108
- 239000000556 agonist Substances 0.000 abstract description 21
- 230000024245 cell differentiation Effects 0.000 abstract description 14
- 210000001744 T-lymphocyte Anatomy 0.000 description 109
- 108050003558 Interleukin-17 Proteins 0.000 description 64
- 102000013691 Interleukin-17 Human genes 0.000 description 64
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 59
- 230000014509 gene expression Effects 0.000 description 54
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 36
- 108090000765 processed proteins & peptides Proteins 0.000 description 36
- 229920001184 polypeptide Polymers 0.000 description 34
- 102000004196 processed proteins & peptides Human genes 0.000 description 34
- 102000004127 Cytokines Human genes 0.000 description 28
- 108090000695 Cytokines Proteins 0.000 description 28
- 201000010099 disease Diseases 0.000 description 28
- 230000028327 secretion Effects 0.000 description 28
- 102000004889 Interleukin-6 Human genes 0.000 description 27
- 108090001005 Interleukin-6 Proteins 0.000 description 27
- 239000012634 fragment Substances 0.000 description 26
- 150000001875 compounds Chemical class 0.000 description 23
- 108040002099 interleukin-21 receptor activity proteins Proteins 0.000 description 22
- 102000008640 interleukin-21 receptor activity proteins Human genes 0.000 description 22
- VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 description 21
- 241000699670 Mus sp. Species 0.000 description 18
- 208000023275 Autoimmune disease Diseases 0.000 description 17
- 201000002491 encephalomyelitis Diseases 0.000 description 16
- 102000037865 fusion proteins Human genes 0.000 description 16
- 108020001507 fusion proteins Proteins 0.000 description 16
- 102100037850 Interferon gamma Human genes 0.000 description 14
- 108010074328 Interferon-gamma Proteins 0.000 description 14
- -1 IL-1β Proteins 0.000 description 13
- 239000003814 drug Substances 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 13
- 241001529936 Murinae Species 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 230000001105 regulatory effect Effects 0.000 description 12
- 206010039073 rheumatoid arthritis Diseases 0.000 description 12
- 238000001727 in vivo Methods 0.000 description 11
- 230000001965 increasing effect Effects 0.000 description 11
- 108020004999 messenger RNA Proteins 0.000 description 11
- 230000005012 migration Effects 0.000 description 11
- 238000013508 migration Methods 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 210000002540 macrophage Anatomy 0.000 description 10
- 108060003951 Immunoglobulin Proteins 0.000 description 9
- 102000018358 immunoglobulin Human genes 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 8
- 101001010621 Homo sapiens Interleukin-21 Proteins 0.000 description 8
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 8
- 102100033467 L-selectin Human genes 0.000 description 8
- 210000004700 fetal blood Anatomy 0.000 description 8
- 238000009396 hybridization Methods 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- 239000000651 prodrug Substances 0.000 description 8
- 229940002612 prodrug Drugs 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 101001010593 Homo sapiens Interleukin-21 receptor Proteins 0.000 description 7
- 210000000447 Th1 cell Anatomy 0.000 description 7
- 239000000427 antigen Substances 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 230000006698 induction Effects 0.000 description 7
- 201000006417 multiple sclerosis Diseases 0.000 description 7
- 230000001717 pathogenic effect Effects 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 235000002639 sodium chloride Nutrition 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 108091023040 Transcription factor Proteins 0.000 description 6
- 102000040945 Transcription factor Human genes 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 230000002757 inflammatory effect Effects 0.000 description 6
- 238000012544 monitoring process Methods 0.000 description 6
- 210000005259 peripheral blood Anatomy 0.000 description 6
- 239000011886 peripheral blood Substances 0.000 description 6
- 230000003389 potentiating effect Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 238000011740 C57BL/6 mouse Methods 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 102100026720 Interferon beta Human genes 0.000 description 5
- 108090000467 Interferon-beta Proteins 0.000 description 5
- 108010081690 Pertussis Toxin Proteins 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 230000001363 autoimmune Effects 0.000 description 5
- 210000003169 central nervous system Anatomy 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 230000003248 secreting effect Effects 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 description 4
- 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 description 4
- 108010070675 Glutathione transferase Proteins 0.000 description 4
- 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 description 4
- 101001017968 Homo sapiens Leukotriene B4 receptor 1 Proteins 0.000 description 4
- 102100037611 Lysophospholipase Human genes 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 201000004681 Psoriasis Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 210000004241 Th2 cell Anatomy 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 239000012472 biological sample Substances 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000002975 chemoattractant Substances 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 238000002651 drug therapy Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000002443 helper t lymphocyte Anatomy 0.000 description 4
- 210000005260 human cell Anatomy 0.000 description 4
- 210000002865 immune cell Anatomy 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 208000011231 Crohn disease Diseases 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 101001066288 Gallus gallus GATA-binding factor 3 Proteins 0.000 description 3
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 3
- 101000713602 Homo sapiens T-box transcription factor TBX21 Proteins 0.000 description 3
- 102100022338 Integrin alpha-M Human genes 0.000 description 3
- 108090000978 Interleukin-4 Proteins 0.000 description 3
- 206010023203 Joint destruction Diseases 0.000 description 3
- 206010033799 Paralysis Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 108091008778 RORγ2 Proteins 0.000 description 3
- 102100036840 T-box transcription factor TBX21 Human genes 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 229940125388 beta agonist Drugs 0.000 description 3
- 239000012620 biological material Substances 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 210000004970 cd4 cell Anatomy 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 208000037976 chronic inflammation Diseases 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 238000011223 gene expression profiling Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000007972 injectable composition Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000002932 luster Substances 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 210000003071 memory t lymphocyte Anatomy 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 238000009736 wetting Methods 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101001017969 Homo sapiens Leukotriene B4 receptor 2 Proteins 0.000 description 2
- 102100036672 Interleukin-23 receptor Human genes 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 102100022118 Leukotriene A-4 hydrolase Human genes 0.000 description 2
- 102100033375 Leukotriene B4 receptor 2 Human genes 0.000 description 2
- 108020002496 Lysophospholipase Proteins 0.000 description 2
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108010083674 Myelin Proteins Proteins 0.000 description 2
- 102000006386 Myelin Proteins Human genes 0.000 description 2
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 108010058864 Phospholipases A2 Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 241000219061 Rheum Species 0.000 description 2
- 102100034201 Sclerostin Human genes 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 102100026159 Tomoregulin-1 Human genes 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 102100020722 WAP, Kazal, immunoglobulin, Kunitz and NTR domain-containing protein 1 Human genes 0.000 description 2
- 102100036021 WAP, Kazal, immunoglobulin, Kunitz and NTR domain-containing protein 2 Human genes 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 229940114079 arachidonic acid Drugs 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000002876 beta blocker Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000035605 chemotaxis Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 235000004626 essential fatty acids Nutrition 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000001476 gene delivery Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 2
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000000644 isotonic solution Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 108010072713 leukotriene A4 hydrolase Proteins 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 238000002493 microarray Methods 0.000 description 2
- 230000002025 microglial effect Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 206010028417 myasthenia gravis Diseases 0.000 description 2
- 210000005012 myelin Anatomy 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000003196 serial analysis of gene expression Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 238000012384 transportation and delivery Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 239000002691 unilamellar liposome Substances 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 1
- UOTMYNBWXDUBNX-UHFFFAOYSA-N 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinolin-2-ium;chloride Chemical compound Cl.C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 UOTMYNBWXDUBNX-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 102100025440 BMP-binding endothelial regulator protein Human genes 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- 201000002829 CREST Syndrome Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000022621 Caronte Diseases 0.000 description 1
- 241000202252 Cerberus Species 0.000 description 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
- 102100032765 Chordin-like protein 1 Human genes 0.000 description 1
- 102100032766 Chordin-like protein 2 Human genes 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 102100032759 Cysteine-rich motor neuron 1 protein Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102100035784 Decorin Human genes 0.000 description 1
- 108090000738 Decorin Proteins 0.000 description 1
- 102100036411 Dermatopontin Human genes 0.000 description 1
- 101710088341 Dermatopontin Proteins 0.000 description 1
- 206010067671 Disease complication Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 102000016970 Follistatin Human genes 0.000 description 1
- 108010014612 Follistatin Proteins 0.000 description 1
- 108010012820 Follistatin-Related Proteins Proteins 0.000 description 1
- 102000019203 Follistatin-Related Proteins Human genes 0.000 description 1
- 102100029378 Follistatin-related protein 1 Human genes 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 101710142641 G-protein coupled receptor-associated sorting protein 1 Proteins 0.000 description 1
- 101710142639 G-protein coupled receptor-associated sorting protein 2 Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000003807 Graves Disease Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 102100038367 Gremlin-1 Human genes 0.000 description 1
- 102100038353 Gremlin-2 Human genes 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000934632 Homo sapiens BMP-binding endothelial regulator protein Proteins 0.000 description 1
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 1
- 101000941971 Homo sapiens Chordin-like protein 1 Proteins 0.000 description 1
- 101000941976 Homo sapiens Chordin-like protein 2 Proteins 0.000 description 1
- 101000942095 Homo sapiens Cysteine-rich motor neuron 1 protein Proteins 0.000 description 1
- 101001062535 Homo sapiens Follistatin-related protein 1 Proteins 0.000 description 1
- 101001032872 Homo sapiens Gremlin-1 Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 101000578353 Homo sapiens Nodal modulator 2 Proteins 0.000 description 1
- 101000836765 Homo sapiens Protein amnionless Proteins 0.000 description 1
- 101000711796 Homo sapiens Sclerostin Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 101000834937 Homo sapiens Tomoregulin-1 Proteins 0.000 description 1
- 101000834948 Homo sapiens Tomoregulin-2 Proteins 0.000 description 1
- 101000855019 Homo sapiens WAP, Kazal, immunoglobulin, Kunitz and NTR domain-containing protein 1 Proteins 0.000 description 1
- 101000803329 Homo sapiens WAP, Kazal, immunoglobulin, Kunitz and NTR domain-containing protein 2 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102100030699 Interleukin-21 receptor Human genes 0.000 description 1
- 101710195550 Interleukin-23 receptor Proteins 0.000 description 1
- 206010023230 Joint stiffness Diseases 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102100025744 Mothers against decapentaplegic homolog 1 Human genes 0.000 description 1
- 102100025751 Mothers against decapentaplegic homolog 2 Human genes 0.000 description 1
- 101710143123 Mothers against decapentaplegic homolog 2 Proteins 0.000 description 1
- 102100025748 Mothers against decapentaplegic homolog 3 Human genes 0.000 description 1
- 101710143111 Mothers against decapentaplegic homolog 3 Proteins 0.000 description 1
- 102100025725 Mothers against decapentaplegic homolog 4 Human genes 0.000 description 1
- 101710143112 Mothers against decapentaplegic homolog 4 Proteins 0.000 description 1
- 102100030610 Mothers against decapentaplegic homolog 5 Human genes 0.000 description 1
- 101710143113 Mothers against decapentaplegic homolog 5 Proteins 0.000 description 1
- 102100030608 Mothers against decapentaplegic homolog 7 Human genes 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101001032860 Mus musculus Gremlin-2 Proteins 0.000 description 1
- 101100260032 Mus musculus Tbx21 gene Proteins 0.000 description 1
- 101100369076 Mus musculus Tdgf1 gene Proteins 0.000 description 1
- 108010000123 Myelin-Oligodendrocyte Glycoprotein Proteins 0.000 description 1
- 102100023302 Myelin-oligodendrocyte glycoprotein Human genes 0.000 description 1
- 108050003738 Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 102100027967 Nodal modulator 2 Human genes 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 102100027097 Protein amnionless Human genes 0.000 description 1
- 108091008731 RAR-related orphan receptors α Proteins 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 101700032040 SMAD1 Proteins 0.000 description 1
- 101700026522 SMAD7 Proteins 0.000 description 1
- 101700031501 SMAD9 Proteins 0.000 description 1
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 108050006698 Sclerostin Proteins 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 102000049870 Smad8 Human genes 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 108091005735 TGF-beta receptors Proteins 0.000 description 1
- 101710175559 Tomoregulin-1 Proteins 0.000 description 1
- 102100026160 Tomoregulin-2 Human genes 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 102100021161 Vasorin Human genes 0.000 description 1
- 101710090241 Vasorin Proteins 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 101710160039 WAP, Kazal, immunoglobulin, Kunitz and NTR domain-containing protein 1 Proteins 0.000 description 1
- 101710160038 WAP, Kazal, immunoglobulin, Kunitz and NTR domain-containing protein 2 Proteins 0.000 description 1
- 208000027207 Whipple disease Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 108010004469 allophycocyanin Proteins 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 230000003172 anti-dna Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 238000009640 blood culture Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 102000006533 chordin Human genes 0.000 description 1
- 108010008846 chordin Proteins 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 230000001712 encephalitogenic effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- LVASCWIMLIKXLA-LSDHHAIUSA-N halofuginone Chemical compound O[C@@H]1CCCN[C@H]1CC(=O)CN1C(=O)C2=CC(Cl)=C(Br)C=C2N=C1 LVASCWIMLIKXLA-LSDHHAIUSA-N 0.000 description 1
- 229950010152 halofuginone Drugs 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000024949 interleukin-17 production Effects 0.000 description 1
- 230000005651 interleukin-17A production Effects 0.000 description 1
- 108040001844 interleukin-23 receptor activity proteins Proteins 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 230000008407 joint function Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000011545 laboratory measurement Methods 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000001077 lymphatic endothelium Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 102000045246 noggin Human genes 0.000 description 1
- 108700007229 noggin Proteins 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000002966 oligonucleotide array Methods 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960003073 pirfenidone Drugs 0.000 description 1
- ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 201000006292 polyarteritis nodosa Diseases 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 229920002721 polycyanoacrylate Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 230000002516 postimmunization Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000001603 reducing effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 208000010157 sclerosing cholangitis Diseases 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000007939 sustained release tablet Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 229940117013 triethanolamine oleate Drugs 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 229930195724 β-lactose Natural products 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
Definitions
- Th17 cells a new population of effector cells, Th17 cells. The discovery of these cells has had a major impact on the understanding of immune processes not readily explained by the Th1/Th2 paradigm. Importantly, Th17 cells have been associated with the pathogenesis of human autoimmune diseases including multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, and psoriasis.
- Th17 cells are differentiated, expansion, and function in human cells, in association with rodent models, and a method for specifically identifying Th17 cells remain important goals in the exploration of autoimmune and other human diseases.
- the present embodiments provide for the differentiation of human Th17 cells. More specifically, the present invention refines and extends the understanding of the regulation of IL-17A secretion from human CD4 + T cells, and defines the conditions required for human Th17 cell differentiation.
- the invention provides for a method of increasing the differentiation of human Th17 cells from a population of human nave CD4 + T cells by contacting the T cells with TGF- 62 and IL-21 in amounts sufficient to increase human Th17 cell differentiation.
- Another embodiment provides for a method of regulating the level of expression of IL-17 from human nave CD4 + T cells by contacting said cells with TGF- ⁇ and IL-21 in amounts sufficient to increase IL-17 expression.
- Yet another embodiment provides a method for increasing Th17 cell activity and/or Th17 cell number by (optionally) identifying a cell (a T cell), or a cell population, where Th17 differentiation is desired, and contacting said cell or cell population with a TGF- ⁇ agonist and a IL-21 agonist in an amount sufficient to increase differentiation into Th17 cells, thereby increasing Th17 cell activity and/or cell number.
- the present invention also provide for a method for inhibiting precursor T cell or T cell population differentiation into a Th17 cell or Th17 cell population by contacting the T cell or T cell population with an antagonist of a TGF- ⁇ and IL-21, or a TGF- ⁇ R and IL-21R, in amounts sufficient to inhibit Th17 cell differentiation.
- An alternative embodiment provides a method for modulating one or more of: IL-17 activity, expression, secretion, or processing, in a T cell or a Th17 cell, or a cell population thereof, is provided by (optionally) identifying a cell in which modulation (increase or reduction) of the activity or level of IL-17 is desired; and contacting said cell or cell population with an amount of TGF- ⁇ /IL-21 modulators, e.g., TGF- ⁇ IL-21 agonists or antagonists, sufficient to modulate the activity or level of IL-17 in said cell or cell population.
- TGF- ⁇ /IL-21 modulators e.g., TGF- ⁇ IL-21 agonists or antagonists
- the migration activity of Th17 cells can be inhibited by U75-302, an antagonist of the Th17-specific leukotriene B4.
- the migration activity of Th17 cells can be inhibited by podoplanin.
- the present invention also provides for compositions, methods, and kits for identifying Th17 cells, and for diagnosing and/or monitoring Th17-associated autoimmune diseases. More specifically, the present invention identifies surface molecules specifically up-regulated in Th17 cells.
- the molecule is the receptor for leukotreine B4 (LTBR4, also called BLT1).
- the molecule is podoplanin.
- the present invention also relates to the use of TGF- ⁇ and IL-21 or agonists thereof for increasing the differentiation of human Th17 cells from a population of nave CD4+ T cells.
- the present invention also relates to the use of antagonists of TGF- ⁇ and IL-21 to inhibit the differentiation of a T cell or T cell population into a Th17 cell or Th17 cell population.
- the present invention also relates to the use of TGF- ⁇ and IL-21 or agonists thereof to increase the expression, activity, secretion or processing of IL-17 in a T cell or T cell population.
- the present invention also relates to the use of antagonists of TGF- ⁇ and IL-21 to decrease the expression, activity, secretion or processing of IL-17 in a T cell or T cell population.
- the present invention also relates to the use of an antagonist of TGF- ⁇ and an antagonist of IL-21 in the preparation of a medicament for the treatment of a disorder involving or mediated by Th17 cell activity.
- FIGS. 1A to 1C present data showing that TGF- ⁇ and IL-21 promote Th17 differentiation from na ⁇ ve CD4 + T cells.
- FIG. 1A shows CD4 + T cells obtained from the peripheral blood of healthy subjects, sorted into populations enriched for na ⁇ ve (CD4 + CD25 ⁇ CD62L + CD45RA hi ) or central memory (Tcm) (CD4 + CD25 ⁇ CD62L + CD45RA ⁇ ) T helper cells.
- FIG. 1B shows sorted T cell populations that were stimulated for seven days in the presence of the indicated cytokines, at which point supernatants were collected and assessed for IFN- ⁇ and IL-17A by ELISA. Error bars represent the standard deviation among three independent experiments using T cells from three unrelated subjects. Induction of IL-17A secretion by a combination of TGF- ⁇ and IL-21 is highly significant (p ⁇ 0.01).
- FIG. 1C shows na ⁇ ve CD4 + T cells stimulated in the presence or absence of TGF- ⁇ and IL-21 for seven days, at which point cells were washed, stimulated for five hours with PMA/ionomycin, and stained for intracellular expression of IL-17 and IFN- ⁇ . Comparable results have been obtained in five unrelated donors.
- FIGS. 2A to 2D demonstrate that TGF- ⁇ and IL-21 induces RORC2 in na ⁇ ve CD4 + T cells.
- FIG. 2A shows nave CD4 + T cells obtained from the peripheral blood of healthy subjects stimulated for seven days in the presence of the indicated cytokines, at which point RNA was collected and levels of RORC2, Tbet, GATA-3, IL-23R, and FoxP3 were measured by quantitative RT-PCR. The mean fold-induction (relative to T cells stimulated in the absence of exogenous cytokines) and standard error among three independent experiments using T cells from three unrelated subjects are represented.
- FIG. 2B shows a mean fold-induction and standard error of IL-21 and IL-22 for three independent experiments.
- FIG. 2C shows CD4 + T cells obtained from cord blood sorted into a population enriched for nave (CD4 + CD25 ⁇ CD62L + CD45RA hi ) T helper cells. Sorted T cells were stimulated for seven days in the presence of the indicated cytokines, at which point RNA was collected and levels of IL-17A and RORC2 were measured by quantitative RT-PCR. Mean expression and standard error are reported based on three independent experiments using cord blood from three distinct donors.
- FIG. 2D reflects intracytoplasmic staining of IL-17 and IFN- ⁇ from cord blood naive T cells after seven days of differentiation. Similar results were seen in another independent assay.
- FIG. 3 presents data demonstrating that LTB4 induces the selective chemotaxis of Th17 cells.
- Th17 or Th1 cells alone or together with different concentrations of LTB4 inhibitor, U75-302 were added to the upper wells of chemotaxis chambers with 10 ⁇ 8 M of LTB4 in the lower wells.
- Cells were kept at 37° C. in 10% CO 2 for 2 hr.
- Cells from the lower chamber were then stained with anti-CD4 antibody and stimulated for 4 hr with PMA/ionomycin in the presence of Golgi Stop. Cells were permeabilized and stained intracellularly for IL-17 or IFN- ⁇ .
- the chemotactic index was calculated by dividing the number of CD4 + IL-17 + (for Th17 cells) or CD4 + IFN- ⁇ + (for TH1 cells) migrated cells in LTB4-containing wells by the number of CD4 + IL-17 + (for Th17 cells) or CD4 + IFN- ⁇ + (for Th1 cells) cells that migrated spontaneously to media alone.
- FIG. 4 shows the clinical course of autoimmune encephalomyelitis (EAE) in wild type and BLT1 knock-out (BLT1 KO) mice immunized with myelin antigen MOG35-55 for the development of EAE.
- EAE autoimmune encephalomyelitis
- BLT1 KO and C57BL/6 wild type mice were immunized with MOG35-55 and pertussis toxin.
- Mice were scored according to an EAE scale from 0 to 5.
- the graph represents the clinical course of EAE over time.
- FIG. 5 shows an EAE course in C57BL/6 mice treated with anti-podoplanin antibody or control PBS.
- C57BL/6 mice were immunized with MOG35-55 plus pertussis toxin and injected with PBS or 100 ⁇ g of anti-podoplanin antibody on day 0, 2, 4, 6, 8 post-immunization.
- FIG. 6 is a heat map of gene expression profiling from na ⁇ ve CD4 + T cells activated in the presence of no cytokine, IL-6, TGF- ⁇ , and TGF- ⁇ plus IL-6 (Th17 cells).
- Na ⁇ ve CD4 + T cells from C57BL/6 mice were stimulated with anti-CD3 and anti-CD28 antibodies in the presence of the different cytokines indicated mRNA was from these different populations was prepared after three days and gene expression profiling was performed with AFFYMETRIX® chips (Santa Clara, Calif.).
- FIG. 7 shows the relative expression of BLT1 in na ⁇ ve CD4 + T cells stimulated in the presence of different cytokines
- FIG. 8 shows the expression of BLT1 on CD4 + human T cells stimulated in the presence of either no cytokine, or IL-21 plus TGF- ⁇ to induce human Th17 cells.
- FIG. 9 is a bar graph indicating the BLT1 and IL-17 expression in Th subsets.
- Na ⁇ ve CD4 + T cells were stimulated with anti-CD3 and anti-CD28 in the presence of IL-12 and anti-IL-4 for TH1 cells, IL-4 and anti-IFN- ⁇ for TH2 cells and IL-6 and TGF- ⁇ for Th17.
- FIG. 10 presents data on the relative expression of IL-17 and podoplanin in CD4 + T cells stimulated in the presence of different cytokines
- FIG. 11 shows the surface expression of podoplanin on different Th cell subsets.
- FIG. 12 demonstrates IL-17 and podoplanin expression on macrophages and microglia from the CNS during the course of EAE.
- C57BL6 mice were immunized with MOG35-55 and pertussis toxin. When mice were paralyzed, at the peak of the disease, the CNS was collected and single cell suspensions were prepared. Macrophages (CD11b + , CD45RB hi ) and microglial cells (CD11b + , CD45RB low ) were sorted by flow cytometry. mRNA from these two populations was prepared and the expression of IL-17 and podoplanin determined by real time PCR using specific primers and probes.
- Th cells CD4 + T helper cells (Th cells) of the adaptive immunity system have evolved to protect host against specific pathogens. Th cells have been divided into three subsets depending on both the cytokines that they produce and the effector functions that they accomplish. These Th cell subsets are designated TH1, TH2, and Th17 cells. Recently, Th17 cells have emerged as potent inducers of inflammation and autoimmune diseases. The mechanisms used by Th17 cells to accomplish their pathogenic functions remain elusive, driving the need for further understanding into the differentiation, characterization, and function of human Th17 cells.
- the present invention defines the conditions required for human Th17 cell differentiation, and compositions and methods useful in modulating human Th17 cell differentiation and functionality.
- TGF- ⁇ and IL-6 are not, however, capable of differentiating human Th17 cells. Wilson et al., 2007; Acosta-Rodriguez et al, 8 Nature Immunol. 942-49 (2007). It has been suggested that TGF- ⁇ may, in fact, suppress the generation of human Th17 cells. Evans et al., 104 P.N.A.S. 17034-39 (2007). Instead, it has recently been shown that the cytokines IL-1 ⁇ , IL-6, and IL-23 are capable of driving IL-17 secretion in short-term CD4 + T cell lines isolated from human peripheral blood (Laurence & Shea, 8 Nature Immunol.
- the present invention provides that although IL-1 ⁇ and IL-6 induce IL-17A secretion from human central memory CD4 + T cells, TGF- ⁇ and IL-21 uniquely promote the differentiation of human na ⁇ ve CD4 + T cells into Th17 cells, accompanied by expression of RORC2.
- the present invention will now facilitate the investigation of the role played by the population of Th17 cells in human inflammatory disease.
- the cells enriched for a na ⁇ ve phenotype were uniformly positive for CCR7 expression. These two T cell populations were then stimulated with plate-bound anti-CD3 and soluble anti-CD28 monoclonal antibodies for seven days in serum-free medium containing different combinations of cytokines implicated in CD4 + T cell differentiation. As previously reported, the cytokine interleukin- ⁇ induced the greatest amount of IL-17A secretion from Tcm ( FIG. 1B ). The addition of IL-6 alone had little effect on induction of IL-17A, and when added with IL-1 ⁇ had no additive or synergistic effect on IL-17A production. Addition of IL-23 was also able to modestly enhance IL-17A secretion from Tcm. IL-1 ⁇ either alone or together with IL-6 failed, however, to induce IL-17A secretion from na ⁇ ve CD4 + T cells.
- TGF- ⁇ and IL-21 were uniquely able to induce Th17 differentiation.
- IL-21, IL-1 ⁇ , or IL-6 induced significant amounts of IFN- ⁇ secretion from na ⁇ ve T cells
- TGF- ⁇ IL-1 ⁇
- IL-6 induced significant amounts of IFN- ⁇ secretion from na ⁇ ve T cells
- TGF- ⁇ suppressed IFN- ⁇ secretion and induced differentiation of Th17 cells.
- Intracytoplasmic staining demonstrated, in agreement with ELISA results, that the combination of TGF- ⁇ and IL-21 differentiated CD4 + T cells that secreted only IL-17A and no IFN- ⁇ ( FIG. 1C ).
- FIG. 1C When starting with FACS-isolated na ⁇ ve CD4 + T cells, between 10%-15% of CD4 + T cells secrete IL-17A after just seven days of differentiation.
- Th17 differentiation coincides with expression of murine ROR ⁇ t, a transcription factor critical for the differentiation of murine IL-17-secreting T cells.
- RORC2 is the human homologue of murine ROR ⁇ t, thus, quantitative RT-PCR was used to evaluate mRNA levels of RORC2 and other molecules implicated in Th17 differentiation.
- the combination of TGF- ⁇ and IL-21 induced high levels of RORC2 ( FIG. 2A ), consistent with their ability to induce IL-17A secretion from na ⁇ ve human CD4 + T cells. It was of particular interest that the combination of TGF- ⁇ and IL-6 that induces Th17 differentiation in murine T cells also induced expression of RORC2 in na ⁇ ve human CD4 cells.
- T-bet is the master regulator for IFN- ⁇ secreting Th1 cells
- GATA-3 induces IL-4 secreting Th2 cells.
- mRNA expression levels of T-bet were highly concordant with amounts of IFN- ⁇ secretion and were consistent with findings that although TGF- ⁇ and IL-21 induce Th17 cell differentiation with RORC2 expression, TGF- ⁇ suppresses the induction of T-bet by IL-21. Similarly, there was no induction of GATA-3 with TGF- ⁇ and IL-21.
- the expression of the Treg transcription factor FoxP3 was also examined. As has been previously reported in both murine and human systems, FoxP3 was induced by TGF- ⁇ . This induction of FoxP3 was inhibited by both IL-6 and to a greater extent IL-21, transcription factors that induce RORC2. Thus, although the induction of RORC2 and FoxP3 transcription factors was highly similar between murine and human na ⁇ ve CD4 cells, the induction of IL-17A by IL-6 in combination with TGF- ⁇ is discordant between the species.
- IL-21 significantly up-regulated IL-21, though IL-1 ⁇ induced even greater amounts of IL-21 mRNA ( FIG. 2B ).
- IL-21 also induced IL-22 mRNA levels in na ⁇ ve CD4 + T cells in the absence of any exogenous IL-23.
- TGF- ⁇ in contrast, suppressed the expression of IL-21 and IL-22 mRNA induced by IL-21 ( FIG. 2B ).
- TGF- ⁇ and IL-21 are critical in the differentiation of both human and murine Th17 cells.
- the present invention refines and extends the understanding of the regulation of IL-17A secretion from human CD4 + T cells, and defines the conditions required for human Th17 cell differentiation.
- IL-1 ⁇ together with IL-6 or IL-23 can induce IL-17A secretion, but these cytokines induce IL-17A expression from human memory CD4 + T cells and not from human na ⁇ ve CD4 + T cells.
- TGF- ⁇ and IL-21, in combination, is required for the differentiation of Th17 cells from human na ⁇ ve T cells.
- the IL-1 ⁇ and IL-6 induced during the early stages of an inflammatory response may act on memory T cells to promote IL-17 and IL-21 secretion, with induced IL-21 able to synergize with TGF- ⁇ to promote differentiation of Th17 cells from na ⁇ ve CD4 + T cells.
- the general immunosuppressive properties of TGF- ⁇ may be responsible for suppression of IFN- ⁇ induced by IL-21 or IL-6. Nevertheless, the simple lack of IFN- ⁇ is not sufficient to promote Th17 differentiation from na ⁇ ve CD4 + T cells as Th17 differentiation was not achieved with a combination of TGF- ⁇ and IL-6 when IFN- ⁇ secretion was well-suppressed.
- TGF- ⁇ A wide range of doses of TGF- ⁇ were examined, ranging from 1 ng/ml to 100 ng/ml, and, indeed, at high doses of TGF- ⁇ all differentiation/proliferation was suppressed.
- IL-21 alone does not induce human Th17 differentiation, which requires the presence of TGF- ⁇ .
- these data indicate that IL-21 does not promote Th17 differentiation simply by suppressing TREG activity.
- T cells may produce sufficient amounts of TGF- ⁇ to synergize with IL-21 to promote Th17 differentiation
- the na ⁇ ve CD4 + T cells represented herein did not produce sufficient amounts, as the addition of IL-21 alone was unable to synergize with endogenous levels of TGF- ⁇ to promote IL-17 secretion.
- the experimental approach simultaneously comparing both na ⁇ ve and memory cell populations in response to cytokine combinations allows the more definitive statements about the cell populations that respond to particular cytokines, as examined by others: that IL-1 ⁇ and IL-6 induce IL-17 secretion from memory CD4 + T cells, and that TGF- ⁇ and IL-21 induce the differentiation of IL-17-secreting CD4 + T cells from na ⁇ ve CD4 + T cells.
- the present invention now allows for the characterization of human inflammatory Th17 responses associated with infection and autoimmune diseases.
- the present embodiments relate to methods and compositions for modulating Th17 cell differentiation and activity.
- the methods and compositions e.g., agonists or antagonists of TGF- ⁇ and IL-21, described herein are useful in treating (e.g., curing, ameliorating, delaying or preventing the onset of, or preventing recurrence or relapse of), or preventing immune-associated ailments such as asthma, allergy, rheumatoid arthritis, multiple sclerosis, lupus, type I diabetes, Crohn's disease, psoriasis, myasthenia gravis, or other autoimmune disorders associated with Th17 differentiation.
- the method includes contacting a human T cell or human T cell population with TGF- ⁇ and IL-21 agonists in amount sufficient to induce differentiation of the T cell or T cell population into a Th17 cell or a Th17 cell population.
- a method of increasing Th17 cell activity and/or Th17 cell number is provided.
- Th17 cell activity and/or cell number can be increased by increasing differentiation (e.g., differentiation of a na ⁇ ve T cell) into a Th17 cell.
- the method includes (optionally) identifying a cell (a T cell), or a cell population, where increased differentiation is desired, and contacting said cell or cell population with a TGF- ⁇ /IL-21 agonists in an amount sufficient to increase differentiation into Th17 cells, thereby increasing Th17 cell activity and/or cell number.
- the contacting step is carried out ex vivo, in vitro, or in vivo.
- the contacting step is performed using mammalian or human cells, or performed in a patient such as a human patient.
- immune cells e.g., T cells as described herein
- the contacting step can be effected by adding one or more TGF- ⁇ /IL-21 modulators (TGF- ⁇ /IL-21 agonists or antagonists), to the culture medium.
- TGF- ⁇ /IL-21 modulators TGF- ⁇ /IL-21 agonists or antagonists
- the method is performed on cells (such as immune or T cells) present in a subject as part of an in vivo (e.g., therapeutic or prophylactic) protocol.
- the TGF- ⁇ agonist can be a TGF- ⁇ polypeptide, a human TGF- ⁇ polypeptide, or an active fragment thereof (e.g., a recombinant human TGF- ⁇ polypeptide or its encoding nucleic acid).
- the TGF- ⁇ agonist may be a fusion protein comprising an TGF- ⁇ polypeptide, e.g., human TGF- ⁇ polypeptide, or a fragment thereof fused to another polypeptide, e.g., an immunoglobulin polypeptide or a portion thereof (e.g., a Fc region of an immunoglobulin polypeptide); an agonist antibody to the TGF- ⁇ receptor TGF- ⁇ R); or a small molecule agonist.
- TGF- ⁇ s Human recombinant TGF- ⁇ s are available commercially (e.g., from Bioclone, Inc., San Diego, Calif., and R&D Systems, Minneapolis, Minn.). Reconstitution and transphosphorylation of recombinant TGF- ⁇ R complexes has also been reported. Ventura et al., 13(23) EMBO J. 5581-89 (1994). TGF- ⁇ expression may also be up-regulated using other cytokines, such as TNF- ⁇ . Sullivan et al., AJRCMB (Jan. 14, 2005).
- the IL-21 agonist can be an IL-21 polypeptide, a human IL-21 polypeptide, or an active fragment thereof (e.g., a recombinant human IL-21 polypeptide or its encoding nucleic acid).
- the IL-21 agonist may be a fusion protein comprising an IL-21 polypeptide, e.g., human IL-21 polypeptide, or a fragment thereof fused to another polypeptide, e.g., an immunoglobulin polypeptide or a portion thereof (e.g., a Fc region of an immunoglobulin polypeptide); an agonist antibody to the IL-21 receptor IL-21R); or a small molecule agonist.
- IL-21 Recombinant human IL-21 is available commercially, e.g., from Prospec Protein Specialists (Rehovot, Israel). Additionally, the nucleotide sequence and amino acid sequence of a human IL-21 is available at Genbank Acc. No. X_011082. Murine IL-21 polypeptides and nucleic acids encoding such polypeptides are exemplified in WO/2004/007682.
- the IL-21 agonist is an agent that increases the activity or level of IL-21 by, e.g., increasing expression, processing and/or secretion of functional IL-21.
- the invention provides for a method for inhibiting precursor T cell or T cell population differentiation into a Th17 cell or Th17 cell population.
- the method includes contacting the T cell or T cell population with an antagonist of a TGF- ⁇ and IL-21, or a TGF- ⁇ R and IL-21R, in amounts sufficient to inhibit Th17 cell differentiation.
- the TGF- ⁇ antagonist may be, for example, an anti-TGF- ⁇ R antibody, an antigen-binding fragment of an anti-TGF- ⁇ R antibody, or a soluble fragment of an TGF- ⁇ R.
- the IL-21 antagonist may be, for example, an anti-IL21R antibody, an antigen-binding fragment of an anti-IL21R antibody, or a soluble fragment of an IL-21R.
- Expression of TGF- ⁇ and IL-21 or their receptor genes may be suppress by RNA interference with, e.g., dsRNA, ssRNA, siRNA, miRNA, artificial derivatives of the forgoing, and the like.
- TGF- ⁇ and IL-21 antagonists that inhibit a TGF- ⁇ /IL-21 mediated T helper cell effect, an agent that blocks or otherwise inhibits the interaction of TGF- ⁇ to a TGF- ⁇ R or IL-21 to an IL-21R can be added to a T cell or a population of T cells.
- These antagonists include, e.g., soluble fragments of TGF- ⁇ or IL-21 polypeptide, TGF- ⁇ R or IL-21R fragments, fusion proteins containing these fragments, and antibodies to these fragments.
- Antibodies include all such classes, subclasses and types of human antibody species.
- antibodies to TGF- ⁇ or TGF- ⁇ R polypeptides also include antibodies to fusion proteins containing TGF- ⁇ or TGF- ⁇ R polypeptides or fragments of TGF- ⁇ or TGF- ⁇ R polypeptides.
- antibodies to IL-21 or IL-21R polypeptides also include antibodies to fusion proteins containing IL-21 or IL-21R polypeptides or fragments of IL-21 or IL-21R polypeptides.
- the TGF- ⁇ antagonist can be, e.g., an antibody (e.g., a monoclonal or single specificity antibody) to TGF- ⁇ or human TGF- ⁇ , or a TGF- ⁇ R polypeptide.
- the antibody may be human, humanized, chimeric, or in vitro generated antibody to human TGF- ⁇ or human TGF- ⁇ R polypeptides.
- the antagonist includes a fragment of a TGF- ⁇ polypeptide, e.g., a TGF- ⁇ binding domain of a TGF- ⁇ polypeptide.
- the antagonist includes a fragment of a TGF- ⁇ R polypeptide, e.g., a TGF- ⁇ binding domain of a TGF- ⁇ R polypeptide.
- the antagonist is a fusion protein comprising the aforesaid TGF- ⁇ or TGF- ⁇ R polypeptides or fragments thereof fused to a second moiety, e.g., a polypeptide (such as an immunoglobulin chain).
- Anti-TGF- ⁇ antibodies are available commercially, e.g., from Invitrogen Corp. (Carlsbad, Calif.), as are numerous antibodies targeting proteins involved in TGF- ⁇ signaling pathways.
- TGF- ⁇ agents that inhibit endogenous TGF- ⁇ include pirfenidone (Liu et al., 5 Am. J. Transplantation, 1266-63 (2005), or other compounds such as those described in U.S. Pat. No. 7,314,939.
- Agents that inhibit TGB-beta signaling include Halofuginone (Figueiro-Ponts et al., 92(2) Haematologica 177 (2007)), Genistein, and curcumin (Santibanez et al., 37(1) Nutrition & Cancer, 49-54 (2000)).
- Additional TGF- ⁇ Superfamily modulators include Amnionless NCAM-1/CD56, BAMBI/NMA Noggin, BMP-1PCP NOMO, Caronte PRDC, Cerberus 1 SKI, Chordin Smad1, Chordin-Like 1 Smad2, Chordin-Like 2 Smad3, COCO Smad4, CRIM1 Smad5, Cripto Smad7, Crossveinless-2 Smad8, Cryptic SOST/Sclerostin, DAN Latent TGF- ⁇ bp1, Decorin Latent TGF- ⁇ bp2, Dermatopontin Latent TGF- ⁇ bp4, FLRG TMEFF1/Tomoregulin-1, Follistatin TMEFF2, Follistatin-like 1 TSG, GASP-1/WFIKKNRP TSK, GASP-2/WFIKKN Vasorin, Gremlin, from R&D Systems (Minneapolis, Minn.).
- the IL-21 antagonist can be, e.g., an antibody (e.g., a monoclonal or single specificity antibody) to IL-21 or human IL-21, or an IL-21R polypeptide.
- the antibody may be human, humanized, chimeric, or in vitro generated antibody to human IL-21 or human IL-21R polypeptides.
- the antagonist includes a fragment of an IL-21 polypeptide, e.g., an IL-21R binding domain of an IL-21 polypeptide.
- the antagonist includes a fragment of an IL-21R polypeptide, e.g., an IL-21 binding domain of an IL-21R polypeptide.
- the antagonist is a fusion protein comprising the aforesaid IL-21 or Il-21R polypeptides or fragments thereof fused to a second moiety, e.g., a polypeptide (such as an immunoglobulin chain).
- IL-21 modulators available commercially include human IL-21R, recombinant human IL-21R/Fc chimera, human IL-21R Allophycocyanin MAb, human IL-21R Biotinylated PAb, human IL-21R MAb, and human IL-21R Phycoerythrin MAb, from R&D Systems (Minneapolis, Minn.).
- Other agents may serve as antagonists of IL-21 gene expression.
- cyclosporine inhibits the IL-21 promoter. Kim et al., 280 (26) J. Biol. Chem. (2005).
- Other IL-21 antagonists are reported in U.S. Pat. No. 7,186,805 and No. 6,929,932, relating to IL-21 mutants that bind IL-21R.
- the invention features a method for modulating, e.g., increasing, or reducing or inhibiting, the activity or level of cytokines, such as IFN- ⁇ or IL-17, in human a T cell or human T cell population.
- a method for modulating one or more of: IL-17 activity, expression, secretion, or processing, in a T cell or a Th17 cell, or a cell population thereof is provided.
- the method includes: (optionally) identifying a cell in which modulation (increase or reduction) of the activity or level of IL-17 is desired; and contacting said cell or cell population with an amount of TGF- ⁇ /IL-21 modulators, e.g., TGF- ⁇ /IL-21 agonists or antagonists, sufficient to modulate the activity or level of IL-17 in said cell or cell population.
- TGF- ⁇ /IL-21 modulators e.g., TGF- ⁇ /IL-21 agonists or antagonists
- the contacting step may be carried out ex vivo, in vitro, or in vivo.
- the contacting step may be performed using human cells, or performed in a human patient.
- the TGF- ⁇ /IL-21 modulators discussed herein may specifically inhibit IL-17 levels or activity, but may also reduce or inhibit the activity or level of other cytokines associated with IL-17 expression or Th17 functionality.
- the TGF- ⁇ /IL-21 agonists inhibit production of IFN- ⁇ by an IFN- ⁇ -producing cell such as a Th1 cell.
- the TGF- ⁇ polypeptide or TGF- ⁇ R polypeptide moiety may be variant TGF- ⁇ or TGF- ⁇ R polypeptide having mutations in the naturally-occurring TGF- ⁇ or TGF- ⁇ R sequence (wild type) that results in an TGF- ⁇ or TGF- ⁇ R sequence more resistant to proteolysis (relative to the non-mutated sequence).
- the IL-21 polypeptide or IL-21R polypeptide moiety may be a variant IL-21 or IL-21R polypeptide having mutations in the naturally-occurring IL-21 or IL-21R sequence (wild type) that results in an IL-21 or IL-21R sequence more resistant to proteolysis (relative to the non-mutated sequence).
- TGF- ⁇ , TGF- ⁇ R, IL-21 and IL-21R, or active fragments of these proteins can be fused to carrier molecules such as immunoglobulins for use in the herein described methods.
- carrier molecules such as immunoglobulins for use in the herein described methods.
- soluble forms of the receptor may be fused through “linker” sequences to the Fc portion of an immunoglobulin or to the Fc portion of the immunoglobulin.
- Other fusions proteins such as those with glutathione S-transferase (GST), LexA, or maltose binding protein (MBP), may also be used.
- TGF- ⁇ , TGF- ⁇ R, IL-21 or IL-21R fusion protein may be linked to one or more additional moieties.
- the fusion protein may additionally be linked to a GST fusion protein in which the fusion protein sequences are fused to the C-terminus of the GST sequences.
- Such fusion proteins can facilitate the purification of the TGF- ⁇ , TGF- ⁇ R, IL-21 or IL-21R fusion proteins.
- the fusion protein includes a heterologous signal sequence (i.e., a polypeptide sequence that is not present in a polypeptide naturally encoded by TGF- ⁇ , TGF- ⁇ R, IL-21 or IL-21R nucleic acid) at its N-terminus.
- a heterologous signal sequence i.e., a polypeptide sequence that is not present in a polypeptide naturally encoded by TGF- ⁇ , TGF- ⁇ R, IL-21 or IL-21R nucleic acid
- the native signal sequence can be removed and replaced with a signal sequence from another protein.
- a chimeric or fusion protein of the invention can be produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different polypeptide sequences are ligated together in-frame in accordance with conventional techniques, e.g., by employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation.
- the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers.
- the methods described herein may be used on cells, e.g., T cells, in vitro or ex vivo.
- the method can be performed on cells present in a subject as part of an in vivo (e.g., therapeutic or prophylactic) protocol.
- the method can be used to treat or prevent a Th17-mediated disorder in a subject.
- the invention provides a method of treating (e.g., curing, suppressing, ameliorating, delaying or preventing the onset of, or preventing recurrence or relapse of) or preventing a Th17-associated disorder in a subject.
- the method includes administering to a subject a TGF- ⁇ /IL-21 antagonists in an amount sufficient to inhibit or reduce Th17 cell activity and/or cell number, thereby treating or preventing a Th17-associated disorder.
- the subject is a mammal, such as a human suffering from a disorder associated with aberrant Th17 cell number or activity, e.g., an immune disorder.
- a disorder associated with aberrant Th17 cell number or activity e.g., an immune disorder.
- the amount sufficient to inhibit or reduce the Th17 cell activity and/or Th17 cell number is an amount sufficient to ameliorate or prevent said disorder.
- the TGF- ⁇ /IL-21 modulators effective in the present invention include pro-drugs.
- pro-drug refers to any compound which releases an active parent drug in vivo when such pro-drug is administered to a mammalian subject.
- Pro-drugs of a compound are typically prepared by modifying one or more functional group(s) present in the compound in such a way that the modification(s) may be cleaved in vivo to release the parent compound.
- pro-drugs include, but are not limited to, esters (e.g., acetate, formate, and benzoate derivatives) and carbamates (e.g., N,N-dimethylaminocarbonyl) of hydroxy functional groups, and amides, carbamates and urea derivatives of amino functional groups, and the like.
- Pro-drug forms often offer advantages of solubility, tissue compatibility, or delayed release in the mammalian organism. See Bundgard, DESIGN OF PRODRUGS, 7-9, 21-24 (Elsevier, Amsterdam, 1985); Silverman, ORGANIC CHEM. OF DRUG DESIGN & DRUG ACTION, 352-401 (Academic Press, San Diego, Calif.).
- the prodrug derivatives of the invention may be combined with other features known to one skilled in the art to enhance bioavailability.
- the TGF- ⁇ /IL-21 modulators described herein can be conveniently provided in pharmaceutical compositions.
- the compositions may be suitable for internal use and include an effective amount of the pharmacologically active compounds of the invention, alone or in combination, with one or more pharmaceutically acceptable carriers.
- the compounds are especially useful in that they have very low, if any toxicity.
- the compounds or their pharmaceutically acceptable salts are administered in amounts which will be sufficient to effect the desired change, such as an increase or decrease Th17 cell differentiation, and are used in the pharmaceutical form most suitable for such purposes.
- the proteins of the present invention are formulated for parenteral, particularly intravenous or subcutaneous, delivery according to conventional methods.
- the bioactive polypeptide or antibody conjugates described herein can be delivered intravenously, intraarterially or intraductally, or may be introduced locally at the intended site of action. Intravenous administration will be by bolus injection or infusion over a typical period of one to several hours.
- pharmaceutical formulations will include a IL-21 protein in combination with a pharmaceutically acceptable vehicle, such as saline, buffered saline, 5% dextrose in water or the like.
- Formulations may further include one or more excipients, preservatives, solubilizers, buffering agents, albumin to prevent protein loss on vial surfaces, etc.
- Therapeutic doses may generally be in the range of 0.1 ⁇ g/kg to 100 ⁇ g/kg of patient weight per day, such as 0.5 ⁇ g/kg-20 ⁇ g/kg per day, with the exact dose determined by the clinician according to accepted standards, taking into account the nature and severity of the condition to be treated, patient traits, etc. Determination of dose is within the level of ordinary skill in the art.
- the proteins may be administered for acute treatment, over one week or less, often over a period of one to three days or may be used in chronic treatment, over several months or years.
- a therapeutically effective amount of the TGF- ⁇ /IL-21 modulators is an amount sufficient to produce a clinically significant change in hematopoietic or immune function
- the active drug component can be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like.
- an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like.
- suitable binders, lubricants, disintegrating agents and coloring agents can also be incorporated into the mixture.
- Suitable binders include starch, magnesium aluminum silicate, starch paste, gelatin, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, polyethylene glycol, waxes and the like.
- Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, silica, talcum, stearic acid, its magnesium or calcium salt and/or polyethyleneglycol and the like.
- Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum starches, agar, alginic acid or its sodium salt, or effervescent mixtures, and the like.
- Diluents include, e.g., lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycine.
- compositions are preferably aqueous isotonic solutions or suspensions, and suppositories are advantageously prepared from fatty emulsions or suspensions.
- the compositions may be sterilized and/or contain adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and/or buffers. In addition, they may also contain other therapeutically valuable substances.
- the compositions are prepared according to conventional mixing, granulating or coating methods, respectively, and contain about 0.1% to 75%, such as about 1% to 50%, of the active ingredient.
- any of the pharmaceutical compositions discussed herein may contain 0.1% to 99%, such as 1% to 70% of the TGF- ⁇ /IL-21, TGF- ⁇ R/IL-21R, TGF- ⁇ /IL-21 agonists, or TGF- ⁇ /IL-21 antagonists.
- the compounds of the invention can also be administered in such oral dosage forms as timed release and sustained release tablets or capsules, pills, powders, granules, elixers, tinctures, suspensions, syrups and emulsions.
- Liquid, particularly injectable compositions can, for example, be prepared by dissolving, dispersing, etc.
- the active compound is dissolved in or mixed with a pharmaceutically pure solvent such as, for example, water, saline, aqueous dextrose, glycerol, ethanol, and the like, to thereby form the injectable solution or suspension.
- a pharmaceutically pure solvent such as, for example, water, saline, aqueous dextrose, glycerol, ethanol, and the like
- solid forms suitable for dissolving in liquid prior to injection can be formulated.
- Injectable compositions are preferably aqueous isotonic solutions or suspensions.
- the compositions may be sterilized and/or contain adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and/or buffers. In addition, they may also contain other therapeutically valuable substances.
- the compounds of the invention can be administered in intravenous (both bolus and infusion), intraperitoneal, subcutaneous or intramuscular form, all using forms well known to those of ordinary skill in the pharmaceutical arts.
- injectables can be prepared in conventional forms, either as liquid solutions or suspensions.
- Parenteral injectable administration is generally used for subcutaneous, intramuscular or intravenous injections and infusions. Additionally, one approach for parenteral administration employs the implantation of a slow-release or sustained-released systems, which assures that a constant level of dosage is maintained, according to U.S. Pat. No. 3,710,795.
- compounds for the invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in that art.
- the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen.
- Other preferred topical preparations include creams, ointments, lotions, aerosol sprays and gels, wherein the concentration of active ingredient would range from 0.1% to 15%, w/w or w/v.
- excipients include pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium carbonate, and the like may be used.
- the active compound defined above may be also formulated as suppositories using for example, polyalkylene glycols, for example, propylene glycol, as the carrier.
- suppositories are advantageously prepared from fatty emulsions or suspensions.
- the compounds of the invention can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles.
- Liposomes can be formed from a variety of phospholipids, containing cholesterol, stearylamine or phosphatidylcholines.
- a film of lipid components is hydrated with an aqueous solution of drug to a form lipid layer encapsulating the drug, as described in U.S. Pat. No. 5,262,564.
- Compounds of the invention may also be delivered by the use of monoclonal antibodies as individual carriers to which the compound molecules are coupled.
- the compounds of the invention may also be coupled with soluble polymers as targetable drug carriers.
- Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropyl-methacrylamide-phenol, polyhydroxyethylaspanamidephenol, or polyethyleneoxidepolylysine substituted with palmitoyl residues.
- the compounds of the invention may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross-linked or amphipathic block copolymers of hydrogels.
- a drug for example, polylactic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross-linked or amphipathic block copolymers of hydrogels.
- the pharmaceutical preparation can include one or more cells that produce the gene delivery system.
- the pharmaceutical composition to be administered may also contain minor amounts of non-toxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents, and other substances such as for example, sodium acetate, triethanolamine oleate, etc.
- non-toxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents, and other substances such as for example, sodium acetate, triethanolamine oleate, etc.
- the dosage regimen utilizing the compounds is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular compound or salt thereof employed.
- An ordinarily skilled physician or veterinarian can readily determine and prescribe the effective amount of the drug required to prevent, counter or arrest the progress of the condition.
- Oral dosages of the invention when used for the indicated effects, will range between about 0.05 mg/day to 1000 mg/day orally. Effective plasma levels of the compounds of the invention range from 0.002 mg to 50 mg per kg of body weight per day. Compounds of the invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three or four times daily.
- a further embodiment of the present invention provides for a method for modulating the activity of a Th17 cell or Th17 cell population comprising contacting said cell or cell population with an amount of Th17 activity modulator sufficient to modulate the activity of a Th17 cell or Th17 cell population.
- Th17 activity modulator sufficient to modulate the activity of a Th17 cell or Th17 cell population.
- the migration activity of Th17 cells may be inhibited by U75-302, an antagonist of the Th17-specific leukotriene B4.
- the migration activity of Th17 cells may be inhibited by podoplanin.
- Th17-activity-specific modulators may be formulated according to the foregoing discussions for use in vitro and in vivo.
- the present invention also provides for the identification of Th17 cells via cell surface molecules that are specifically up-regulated in Th17 cells. More specifically, expression profiling comparing na ⁇ ve T cells differentiated into Th17 cells with T cells cultured in the presence of either IL-6 alone or TGF- ⁇ alone identified genes expressed specifically in Th17 cells (differentiated in the presence of TGF- ⁇ plus IL-6) but not in na ⁇ ve T cells activated in the presence of IL-6, TGF- ⁇ , or no cytokines Consistent with published literature, IL-17A and the transcription factors ROR ⁇ t and ROR ⁇ were up-regulated in Th17 cells compared to cells cultured in other conditions.
- BLT1 the receptor for the leukotriene B4
- podoplanin the receptor for the leukotriene B4
- Th17 cells may be identified in a sample.
- the “sample” or “biological sample” may be any biological material taken either directly from a subject human being (or animal), or after culturing (enrichment). Biological material may include expectorations of any kind, broncheolavages, blood, skin tissue, biopsies, semen, lymphocyte blood culture material, colonies, liquid cultures, faecal samples, urine, etc. Biological material may also include cell cultures or the liquid phase thereof.
- biological sample generally refers to any biological sample (tissue or fluid) containing Th17 cells, and includes blood serum or plasma samples.
- the sample may be collected from a subject, which refers to an individual regardless of health and/or disease status.
- a subject can be a patient, a study participant, a control subject, a screening subject, or any other class of individual from whom a sample is obtained and assessed in the context of the invention.
- a subject can be diagnosed with a disease, can present with one or more symptom of a disease, or a predisposing factor, such as a family (genetic) or medical history (medical) factor, for a disease.
- a subject can be healthy with respect to any of the aforementioned factors or criteria, although the term “healthy” is relative to a specified disease, or disease factor, or disease criterion, and can not be defined to correspond to any absolute evaluation or status.
- an individual defined as healthy with reference to any specified disease or disease criterion can in fact be diagnosed with any other one or more disease, or exhibit any other one or more disease criterion.
- the Th17 cell-specific markers of the present invention can be identified by antibodies.
- Such antibodies can include, but are not limited to polyclonal antibodies, monoclonal antibodies (mAbs), humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab′)2 fragments, fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies, and epitope-binding fragments of any of the above.
- mAbs monoclonal antibodies
- Such antibodies can be used, for example, in the detection Th17 markers in a biological sample, or, alternatively, as a modulator to Th17 functionality as described herein.
- Such antibodies can be utilized as part of autoimmune or other disease treatment methods, and/or can be used as part of diagnostic techniques whereby patients may be tested for abnormal levels of Th17-specific markers.
- Immunoassays generally involve the use of labeled antibody or polypeptide.
- the labels can be, for example, fluorescent, chemiluminescent, radioactive, or dye molecules.
- a particular aspect of the invention provides for molecules capable of recognizing podoplanin and/or BLT1, attached to a substrate.
- the markers of the present invention can also be identified by assessing their expression via nucleic acid molecules. Numerous methods for obtaining expression data are known, and any one or more of these techniques, singly or in combination, are suitable for determining expression profiles in the context of the present invention. For example, expression patterns can be evaluated by northern analysis, PCR, RT-PCR, Taq Man analysis, FRET detection, monitoring one or more molecular beacons, hybridization to an oligonucleotide array, hybridization to a cDNA array, hybridization to a polynucleotide array, hybridization to a liquid microarray, hybridization to a microelectric array, cDNA sequencing, clone hybridization, cDNA fragment fingerprinting, serial analysis of gene expression (SAGE), subtractive hybridization, differential display and/or differential screening. See, e.g., Lockhart & Winzeler 405 Nature 827-36 (2000); U.S. Pat. No. 6,905,827.
- kits for the identification of Th17 cells.
- a kit contains one or more probes, such as antibodies or diagnostic nucleotides.
- the probe can exist as part of a diagnostic nucleotide probe set, or other subset of a candidate library, (e.g., as a cDNA, oligonucleotide, or antibody microarray or reagents for performing an assay on a diagnostic gene set using any expression profiling technology), packaged in a suitable container.
- the kit can further comprise, one or more additional reagents, e.g., substrates, labels, primers, for labeling expression products, tubes and/or other accessories, reagents for collecting blood samples, buffers, e.g., erythrocyte lysis buffer, leukocyte lysis buffer, hybridization chambers, cover slips, etc., as well as a software package, e.g., including the statistical methods of the invention, e.g., as described above, and a password and/or account number for accessing the compiled database.
- the kit optionally further comprises an instruction set or user manual detailing preferred methods of using the diagnostic probes in the methods of the invention.
- Th17 cells can be used to identify or determine (qualitatively or quantitatively) if a subject (e.g., and patient or individual) has Th17 cells.
- Th17 cells may be associated with an autoimmune disorder.
- An autoimmune disorder is defined as a disease state in which a patient's immune system recognizes an antigen in that patient's organs or tissues as foreign and becomes activated. The activated immune cells can then cause damage to the inciting organ or tissue or can damage other organs or tissues.
- the disorder may be caused by a dysregulation of the immune system cells, rather than by the recognition as a self-antigen as foreign. Dysregulated immune cells can secrete inflammatory cytokines that cause systemic inflammation or they can recognize self-antigens as foreign.
- autoimmune diseases include autoimmune hepatitis, multiple sclerosis, myasthenia gravis, Type I diabetes, rheumatoid arthritis, psoriasis, systemic lupus erythematosis, Hashimoto's thyroiditis, Grave's disease, ankylosing spondylitis Sjogrens disease, CREST syndrome, and scleroderma.
- Most of the autoimmune diseases are also chronic inflammatory diseases. This is defined as a disease process associated with long-term (>6 months) activation of inflammatory cells (leukocytes). The chronic inflammation leads to damage of patient organs or tissues.
- Many diseases are chronic inflammatory disorders, but are not know to have an autoimmune basis. Examples include atherosclerosis, congestive heart failure, Crohn's disease, ulcerative colitis, polyarteritis nodosa, Whipple's Disease, and primary sclerosing cholangitis.
- Th17 cells can be useful in monitoring individuals with autoimmune disorders. Monitoring describes the observation of Th17 cell markers to provide useful information about an individual or an individual's health or disease status. “Monitoring” can include determination of prognosis, risk-stratification, selection of drug therapy, assessment of ongoing drug therapy, prediction of outcomes, determining response to therapy, diagnosis of a disease or disease complication, following progression of a disease or providing any information relating to a patients health status.
- RA rheumatoid arthritis
- the Th17-specific cell surface molecules of the present invention can be used in the diagnosis and monitoring of RA.
- RA effects about two million patients in the U.S. and is a chronic and debilitating inflammatory arthritis, particularly involving pain and destruction of the joints.
- RA often goes undiagnosed because patients may have no pain, but the disease is actively destroying the joint.
- Other patients are known to have RA, and are treated to alleviate symptoms, but the rate of progression of joint destruction is not monitored easily.
- Drug therapy is available, but the most effective medicines are toxic (e.g., steroids, methotrexate) and should be used with caution.
- a new class of medications, TNF blockers is effective, but the drugs are expensive, have side effects, and not all patients respond.
- RA disease criteria correspond to disease symptoms (e.g., joint pain, joint swelling and joint stiffness and any of the American College for Rheumatology criteria for the diagnosis of RA, see Arnett et al., 31 Arthr. Rheum. 315-24 (1988), progression of joint destruction (e.g., as measured by serial hand radiographs, assessment of joint function and mobility), surgery, need for medication, additional diagnoses of inflammatory and non-inflammatory conditions, and clinical laboratory measurements including complete blood counts with differentials, CRP, ESR, ANA, Serum IL6, Soluble CD40 ligand, LDL, HDL, Anti-DNA antibodies, rheumatoid factor, C3, C4, serum creatinine, death, hospitalization, and disability due to joint destruction.
- disease symptoms e.g., joint pain, joint swelling and joint stiffness and any of the American College for Rheumatology criteria for the diagnosis of RA, see Arnett et al., 31 Arthr. Rheum. 315-24 (1988)
- disease criteria correspond to response to drug therapy and presence or absence of side-effects or measures of improvement exemplified by the American College of Rheumatology “20%” and “50%” response/improvement rates. See Felson et al., 38 Arthr. Rheum. 531-37 (1995).
- the Th17 markers of the instant invention identify, monitor, and predict disease progression including flaring (acute worsening of disease accompanied by joint pain or other symptoms), response to drug treatment and likelihood of side-effects.
- Th17 cells are potent inducers of inflammation and autoimmune diseases. Th17 cells are found in the target organs of many autoimmune diseases. Until the present invention, however, the absence of known markers on surface of these cells has not allowed the detection and isolation of live Th17 cells from tissues and therefore the characterization of their effector function during autoimmune diseases. The identification of molecules such as BLT1 and podoplanin, specifically expressed on the surface of Th17 cells, will greatly aid basic research regarding these cells, and diagnosis of Th17-associated illness such as multiple sclerosis, psoriasis, rheumatoid arthritis and Crohn's disease.
- PBMCs peripheral blood of healthy subjects or from cord blood (AllCells) in compliance with institutional IRB protocols.
- CD4 + T cells were subsequently isolated by negative selection using magnetic beads (Miltenyi Biotech Inc., Auburn, Calif.).
- Na ⁇ ve (CD25 ⁇ CD62L + CD45RA hi ) and central memory (CD25 ⁇ CD62L ⁇ CD45RA ⁇ ) CD4 + T cells were obtained by staining with the following antibodies: CD62L-FITC, CD4-PerCP, CD45RA-PE-Cy7, CD25-APC-Cy7 (BD Pharmingen, San Diego, Calif.) and were sorted on a FACS Aria (BD Biosciences, Palo Alto, Calif.).
- ⁇ ⁇ ve or central memory CD4 + T cells were stimulated with plate-bound anti-CD3 and soluble CD28 monoclonal antibodies (1 ⁇ g/ml, each) in serum-free X-VIVO15 medium (Biowhittaker Inc., Walkersville, Md.) and cytokines (IL-6, 25 ng/ml; TGF- ⁇ , 5 ng/ml; IL-1 ⁇ , 12.5 ng/ml; IL-21, 25 ng/ml; IL-23, 25 ng/ml) for a period of seven days, at which point supernatants were collected and tested by ELISA for IFN- ⁇ (BD Biosciences) or IL-17A (eBioscience, San Diego, Calif.) using paired antibodies. Intracytoplasmic staining was performed using standard methodologies and anti-IL-17-APC (R&D Systems, Minneapolis, Minn.) and anti-IFN- ⁇ -PE (BD Biosciences) antibodies.
- Antibodies recognizing podoplanin are available commercially from, for example, Abcam Inc. (Cambridge, Mass.) and Santa Cruz Biotechnology, Inc. (Santa Cruz, Calif.). Antibodies to LTB4R1 are available commercially from, for example, Sigma-Aldrich (St. Louis, Mo.) and R&D Systems (Minneapolis, Minn.). The anti-BLT1(LTB4R1):FITC conjugated mAb (202/7B1) was obtained from AbD Serotec (Raleigh, N.C.). See Petersson, et al. (2000) 279 Biochem. Biophys. Res. Commun. 520-25 (2000).
- the anti-podoplanin antibody used in FACS staining was Rat monoclonal 8F11 obtained from MBL International (Woburn, Mass.). See Watanabe et al., 48 Cancer Res. 6411-16 (1988).
- the anti-podoplanin antibody used for in vivo injection was designated 8.1.1., obtained from Studies Hybridoma Bank, University of Iowa (Iowa City, Iowa). See Farr et al., J. Histochem. & Cytochem. (1992); Farr et al., J. Exp. Med. (1992).
- LTB4 Leukotriene B4
- PKA2 cytosolic phospholipase A2
- 5-LO 5-lipoxygenase
- LTB4 hydrolase cytosolic phospholipase A2
- PHA2 cytosolic phospholipase A2
- 5-LO 5-lipoxygenase
- LTB4 hydrolase a potent chemoattractant that triggers the adherence and aggregation of leukocytes to the endothelium and recruits granulocytes and macrophages to the inflammation site. Recent studies have shown that LTB4 may also function as a chemoattractant for T cells.
- BLT1 is selectively induced by the combination of IL-6 and TGF- ⁇ , which also induces IL-17 ( FIG. 7 ) and leads to the generation of Th17 cells.
- na ⁇ ve CD4 + T cells taken from healthy donors and activated with anti-CD3 and anti-CD28 in the presence of a combination of IL-21 and TGF- ⁇ , which induces the differentiation of Th17 cells in human cells, were analyzed the surface expression of BLT1 with a BLT1-specific antibody. In the absence of TH17-differentiating cytokines, only 5% of T cells expressed the BLT1 ( FIG. 8 ).
- BLT1 When human CD4 T cells were differentiated in the presence of IL-21 plus TGF- ⁇ , however, some of the CD4 + T cells expressed BLT1. This shows for the first time that that both BLT1 mRNA and protein are rapidly and specifically expressed on mouse and also human Th17 cells. It may be noted that this selective expression on Th17 cells may be restricted to BLT1: the expression of BLT2 was not observed on Th17 cells but was observed on Th2 cells.
- Podoplanin Expression is Specifically Up-regulated in Th17 Cells
- Podoplanin is another surface molecule identified specifically on Th17 cells.
- Podoplanin is a transmembrane mucin-containing molecule, which is expressed on the lymphatic endothelium and tumor cells under pathogenic conditions 22,23. Kaneko et al., 378 Gene, 52-7 (2006); Wicki & Christofori, 96 Br. J. Cancer 96, 1-5 (2007). So far, no expression of PDP has been described on hematopoetic cells 23. Wicki & Christofori, 2007. This is the first work showing that PDP is expressed on some T cells and more specifically on differentiating Th17 cells ( FIG. 10 ).
- podoplanin constitutes a Th17 specific marker because its expression was not observed in Th1 or Th2 cells ( FIG. 11 ). Therefore, it provides a specific marker to isolate and distinguish Th17 cells with minimal manipulation of T cells.
- IL-17 In addition to Th17 cells, macrophages (CD11b+ cells) from the central nervous system (CNS) of mice with EAE were able to produce IL-17 ( FIG. 12 ). Analysis of the expression of podoplanin on this population revealed that it expressed podoplanin as well. In contrast, microglial cells, did not express significant levels of either IL-17 or podoplanin. Therefore, it appears that podoplanin expression mimics IL-17 expression in both Th17 cells and macrophages, indicating that podoplanin expression can allow the tracking of subsets of pathogenic Th cells (Th17 cells) and also subsets of IL-17-producing pathogenic macrophages.
- Th17 cells pathogenic Th cells
- IL-17-producing pathogenic macrophages subsets of IL-17-producing pathogenic macrophages.
- LTB4 Leukotriene B4
- PKA2 cytosolic phospholipase A2
- 5-LO 5-lipoxygenase
- LTB4 hydrolase cytosolic phospholipase A2
- Jala & Haribabu 25 Trends Immunol 315-22 (2004).
- LTB4 is a potent chemoattractant that triggers the adherence and aggregation of leukocytes to the endothelium and recruits granulocytes and macrophages to the inflammation site. Recent studies have shown that LTB4 may also function as a chemoattractant for T cells.
- LTB4 is involved in the recruitment of different cell types at the site of inflammation, whether the expression of LTB4 could induce the selective migration of Th17 cells was investigated by manipulating its receptor, BLT1. Indeed, LTB4 induced the selective migration of newly differentiated Th17 cells but not Th1 cells ( FIG. 3 ).
- BLT1 also called LTBR1
- BLT2 LTBR2
- U-75302 6-(6-(3R-hydroxy-1E,5Z-undecadien-1-yl)-2-pyridinyl)-1,5S-hexandiol, is a synthetic, specifically binds BLT1.
- Richards et al. 140 Ann. Rev. Respir. Dis. 1712-16 (1989).
- U-75302 is available commercially from, e.g., Cayman Chemical (Ann Arbor, Mich.)). Using U75302 as an antagonist of LTB4, it was shown that LTB4 induced a selective migration of Th17 cells, which could be blocked in a dose dependant manner by the addition of different doses of the LTB4 antagonist U-75302 ( FIG. 3 ).
- BLT1 on Th17 cells also modulates the function of Th17 cells in vivo, as shown herein. This was determined by testing the effect of BLT1 ablation on the development of experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis, in which Th17 cells have been shown to play an important pathogenic role. To do so, BLT1 knock-out (BLT1 KO) and wild type mice were immunized with myelin oligodendrocyte glycoprotein immunodominant peptide sequence MOG35-55 (encephalitogenic peptide) and injected with pertussis toxin. Mice were maintained according to IACUC protocols.
- EAE experimental autoimmune encephalomyelitis
- Podoplanin was identified as a marker for Th17 cells, and its role in the progression of the animal model of multiple sclerosis, EAE, explored herein.
- An anti-podoplanin-specific antibody (Farr et al., 176 J. Exp. Med. 1477-82 (1992)), was injected in vivo into mice undergoing EAE. Although mice that received a control antibody developed severe disease and were paralyzed, the mice that received the anti-podoplanin specific antibody did not develop as severe disease, indicating that the anti-podoplanin antibody inhibited the progression of autoimmune disease.
- Podoplanin has previously been shown to play an important role in the migration and invasiveness of tumor cells. Wicki & Christophori, 96 Br. J. Cancer, 1-5 (2007). Podoplanin was specifically expressed in Th17 cells and IL-17-producing macrophages. Furthermore, the injection of an anti-podoplanin antibody decreased the severity of EAE. Together, these data indicate that podoplanin can modulate the migration of pathogenic Th17 cells and possibly IL-17-producing macrophages.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
- This Application is a divisional application of U.S. application Ser. No. 12/863,373 filed on Jul. 16, 2010, which is a 35 U.S.C. §371 National Phase Entry Application of International Application No. PCT/US09/31477 filed Jan. 21, 2009, which designates the U.S., and which claims the benefit of priority from U.S. patent applications Ser. No. 61/006,541, filed Jan. 18, 2008, and Ser. No. 61/031,824, filed Feb. 27, 2008.
- The invention was made, in part, with government support under grants No. P01 NS038037, No. NS045937 and No. 30843, awarded by the National Institutes of Health. The U.S. government has certain rights in the invention.
- Autoimmune diseases, more than eighty of which have been identified, cause significant morbidity and disability and are notoriously difficult to diagnose. As many as twenty-four million Americans suffer from autoimmune disease, and treatment costs exceed $100 billion annually.
- Recently, a new population of effector cells, Th17 cells, has been identified and implicated in various immune-related conditions. The discovery of these cells has had a major impact on the understanding of immune processes not readily explained by the Th1/Th2 paradigm. Importantly, Th17 cells have been associated with the pathogenesis of human autoimmune diseases including multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, and psoriasis.
- Further understanding of the differentiation, expansion, and function of Th17 cells in human cells, in association with rodent models, and a method for specifically identifying Th17 cells remain important goals in the exploration of autoimmune and other human diseases.
- The present embodiments provide for the differentiation of human Th17 cells. More specifically, the present invention refines and extends the understanding of the regulation of IL-17A secretion from human CD4+ T cells, and defines the conditions required for human Th17 cell differentiation.
- In a one embodiment, the invention provides for a method of increasing the differentiation of human Th17 cells from a population of human nave CD4+ T cells by contacting the T cells with TGF-62 and IL-21 in amounts sufficient to increase human Th17 cell differentiation.
- Another embodiment provides for a method of regulating the level of expression of IL-17 from human nave CD4+ T cells by contacting said cells with TGF-β and IL-21 in amounts sufficient to increase IL-17 expression.
- Yet another embodiment provides a method for increasing Th17 cell activity and/or Th17 cell number by (optionally) identifying a cell (a T cell), or a cell population, where Th17 differentiation is desired, and contacting said cell or cell population with a TGF-β agonist and a IL-21 agonist in an amount sufficient to increase differentiation into Th17 cells, thereby increasing Th17 cell activity and/or cell number.
- The present invention also provide for a method for inhibiting precursor T cell or T cell population differentiation into a Th17 cell or Th17 cell population by contacting the T cell or T cell population with an antagonist of a TGF-β and IL-21, or a TGF-βR and IL-21R, in amounts sufficient to inhibit Th17 cell differentiation.
- An alternative embodiment provides a method for modulating one or more of: IL-17 activity, expression, secretion, or processing, in a T cell or a Th17 cell, or a cell population thereof, is provided by (optionally) identifying a cell in which modulation (increase or reduction) of the activity or level of IL-17 is desired; and contacting said cell or cell population with an amount of TGF-β/IL-21 modulators, e.g., TGF-βIL-21 agonists or antagonists, sufficient to modulate the activity or level of IL-17 in said cell or cell population.
- For example, the migration activity of Th17 cells can be inhibited by U75-302, an antagonist of the Th17-specific leukotriene B4. Similarly, the migration activity of Th17 cells can be inhibited by podoplanin.
- The present invention also provides for compositions, methods, and kits for identifying Th17 cells, and for diagnosing and/or monitoring Th17-associated autoimmune diseases. More specifically, the present invention identifies surface molecules specifically up-regulated in Th17 cells. In an aspect of the invention, the molecule is the receptor for leukotreine B4 (LTBR4, also called BLT1). In another aspect, the molecule is podoplanin.
- The present invention also relates to the use of TGF-β and IL-21 or agonists thereof for increasing the differentiation of human Th17 cells from a population of nave CD4+ T cells.
- The present invention also relates to the use of antagonists of TGF-β and IL-21 to inhibit the differentiation of a T cell or T cell population into a Th17 cell or Th17 cell population.
- The present invention also relates to the use of TGF-β and IL-21 or agonists thereof to increase the expression, activity, secretion or processing of IL-17 in a T cell or T cell population.
- The present invention also relates to the use of antagonists of TGF-β and IL-21 to decrease the expression, activity, secretion or processing of IL-17 in a T cell or T cell population.
- The present invention also relates to the use of an antagonist of TGF-β and an antagonist of IL-21 in the preparation of a medicament for the treatment of a disorder involving or mediated by Th17 cell activity.
-
FIGS. 1A to 1C present data showing that TGF-β and IL-21 promote Th17 differentiation from naïve CD4+ T cells.FIG. 1A shows CD4+ T cells obtained from the peripheral blood of healthy subjects, sorted into populations enriched for naïve (CD4+ CD25− CD62L+ CD45RAhi) or central memory (Tcm) (CD4+ CD25− CD62L+ CD45RA−) T helper cells. -
FIG. 1B shows sorted T cell populations that were stimulated for seven days in the presence of the indicated cytokines, at which point supernatants were collected and assessed for IFN-γ and IL-17A by ELISA. Error bars represent the standard deviation among three independent experiments using T cells from three unrelated subjects. Induction of IL-17A secretion by a combination of TGF-β and IL-21 is highly significant (p<0.01). -
FIG. 1C shows naïve CD4+ T cells stimulated in the presence or absence of TGF-β and IL-21 for seven days, at which point cells were washed, stimulated for five hours with PMA/ionomycin, and stained for intracellular expression of IL-17 and IFN-γ. Comparable results have been obtained in five unrelated donors. -
FIGS. 2A to 2D demonstrate that TGF-β and IL-21 induces RORC2 in naïve CD4+ T cells.FIG. 2A shows nave CD4+ T cells obtained from the peripheral blood of healthy subjects stimulated for seven days in the presence of the indicated cytokines, at which point RNA was collected and levels of RORC2, Tbet, GATA-3, IL-23R, and FoxP3 were measured by quantitative RT-PCR. The mean fold-induction (relative to T cells stimulated in the absence of exogenous cytokines) and standard error among three independent experiments using T cells from three unrelated subjects are represented. -
FIG. 2B shows a mean fold-induction and standard error of IL-21 and IL-22 for three independent experiments. -
FIG. 2C shows CD4+ T cells obtained from cord blood sorted into a population enriched for nave (CD4+ CD25− CD62L+ CD45RAhi) T helper cells. Sorted T cells were stimulated for seven days in the presence of the indicated cytokines, at which point RNA was collected and levels of IL-17A and RORC2 were measured by quantitative RT-PCR. Mean expression and standard error are reported based on three independent experiments using cord blood from three distinct donors. -
FIG. 2D reflects intracytoplasmic staining of IL-17 and IFN-γ from cord blood naive T cells after seven days of differentiation. Similar results were seen in another independent assay. -
FIG. 3 presents data demonstrating that LTB4 induces the selective chemotaxis of Th17 cells. Th17 or Th1 cells alone or together with different concentrations of LTB4 inhibitor, U75-302, were added to the upper wells of chemotaxis chambers with 10−8M of LTB4 in the lower wells. Cells were kept at 37° C. in 10% CO2 for 2 hr. Cells from the lower chamber were then stained with anti-CD4 antibody and stimulated for 4 hr with PMA/ionomycin in the presence of Golgi Stop. Cells were permeabilized and stained intracellularly for IL-17 or IFN-γ. The chemotactic index was calculated by dividing the number of CD4+ IL-17+ (for Th17 cells) or CD4+ IFN-γ+ (for TH1 cells) migrated cells in LTB4-containing wells by the number of CD4+ IL-17+ (for Th17 cells) or CD4+ IFN-γ+ (for Th1 cells) cells that migrated spontaneously to media alone. -
FIG. 4 shows the clinical course of autoimmune encephalomyelitis (EAE) in wild type and BLT1 knock-out (BLT1 KO) mice immunized with myelin antigen MOG35-55 for the development of EAE. BLT1 KO and C57BL/6 wild type mice were immunized with MOG35-55 and pertussis toxin. Mice were scored according to an EAE scale from 0 to 5. The graph represents the clinical course of EAE over time. -
FIG. 5 shows an EAE course in C57BL/6 mice treated with anti-podoplanin antibody or control PBS. C57BL/6 mice were immunized with MOG35-55 plus pertussis toxin and injected with PBS or 100 μg of anti-podoplanin antibody onday -
FIG. 6 is a heat map of gene expression profiling from naïve CD4+ T cells activated in the presence of no cytokine, IL-6, TGF-β, and TGF-β plus IL-6 (Th17 cells). Naïve CD4+ T cells from C57BL/6 mice were stimulated with anti-CD3 and anti-CD28 antibodies in the presence of the different cytokines indicated mRNA was from these different populations was prepared after three days and gene expression profiling was performed with AFFYMETRIX® chips (Santa Clara, Calif.). -
FIG. 7 shows the relative expression of BLT1 in naïve CD4+ T cells stimulated in the presence of different cytokines Nave CD4+ T cells from C57B16 mice were stimulated with anti-CD3 and anti-CD28 in the presence of different cytokines IL-17 and BLT1 mRNAs relative expression was determined by real time PCR, with specific primers and probes after three days of in vitro culture. -
FIG. 8 shows the expression of BLT1 on CD4+ human T cells stimulated in the presence of either no cytokine, or IL-21 plus TGF-β to induce human Th17 cells. -
FIG. 9 is a bar graph indicating the BLT1 and IL-17 expression in Th subsets. Naïve CD4+ T cells were stimulated with anti-CD3 and anti-CD28 in the presence of IL-12 and anti-IL-4 for TH1 cells, IL-4 and anti-IFN-γ for TH2 cells and IL-6 and TGF-β for Th17. -
FIG. 10 presents data on the relative expression of IL-17 and podoplanin in CD4+ T cells stimulated in the presence of different cytokines -
FIG. 11 shows the surface expression of podoplanin on different Th cell subsets. -
FIG. 12 demonstrates IL-17 and podoplanin expression on macrophages and microglia from the CNS during the course of EAE. C57BL6 mice were immunized with MOG35-55 and pertussis toxin. When mice were paralyzed, at the peak of the disease, the CNS was collected and single cell suspensions were prepared. Macrophages (CD11b+, CD45RBhi) and microglial cells (CD11b+, CD45RBlow) were sorted by flow cytometry. mRNA from these two populations was prepared and the expression of IL-17 and podoplanin determined by real time PCR using specific primers and probes. - It should be understood that this invention is not limited to the particular methodology, protocols, and reagents, etc., described herein and as such may vary. The terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention, which is defined solely by the claims.
- As used herein and in the claims, the singular forms include the plural reference and vice versa unless the context clearly indicates otherwise. Other than in the operating examples, or where otherwise indicated, all numbers expressing quantities of ingredients or reaction conditions used herein should be understood as modified in all instances by the term “about.”
- All patents and other publications identified are expressly incorporated herein by reference for the purpose of describing and disclosing, for example, the methodologies described in such publications that might be used in connection with the present invention. These publications are provided solely for their disclosure prior to the filing date of the present application. Nothing in this regard should be construed as an admission that the inventors are not entitled to antedate such disclosure by virtue of prior invention or for any other reason. All statements as to the date or representation as to the contents of these documents is based on the information available to the applicants and does not constitute any admission as to the correctness of the dates or contents of these documents.
- Unless defined otherwise, all technical and scientific terms used herein have the same meaning as those commonly understood to one of ordinary skill in the art to which this invention pertains. Although any known methods, devices, and materials may be used in the practice or testing of the invention, the methods, devices, and materials in this regard are described herein.
- CD4+ T helper cells (Th cells) of the adaptive immunity system have evolved to protect host against specific pathogens. Th cells have been divided into three subsets depending on both the cytokines that they produce and the effector functions that they accomplish. These Th cell subsets are designated TH1, TH2, and Th17 cells. Recently, Th17 cells have emerged as potent inducers of inflammation and autoimmune diseases. The mechanisms used by Th17 cells to accomplish their pathogenic functions remain elusive, driving the need for further understanding into the differentiation, characterization, and function of human Th17 cells.
- The present invention defines the conditions required for human Th17 cell differentiation, and compositions and methods useful in modulating human Th17 cell differentiation and functionality.
- The recent discovery of CD4+ T cells characterized by secretion of IL-17 (Th17 cells) and the regulatory, FoxP3+ CD4 T cell (nTREG) have had a major impact on the understanding of immune processes that are not readily explained by the traditional TH1/TH2 paradigm. Kikly et al., 18 Curr. Opin. Immunol. 670-75 (2006); Wilson et al., 8 Nature Immuno. 950-57 (2007). Recent work demonstrated that TGF-β and IL-6 are responsible for the differentiation of naïve murine T cells into Th17 cells, and it has been proposed that IL-23 may play a critical role in stabilization of the Th17 phenotype. Bettelli et al., 441 Nature 235-58 (2006); Mangan et al., 441 Nature 231-34 (2006); Veldhoen et al., 24 Immunity 179-89 (2006). It has also been discovered that a second pathway in which a combination of TGF-β and IL-21 is capable of inducing differentiation of murine Th17 cells in the absence of IL-6. Korn et al., 448 Nature 484-87 (2007); Nurieva et al., 448 Nature 480-83 (2007); Zhou et al., 8 Nature Immunol. 967-74 (2007).
- TGF-β and IL-6 are not, however, capable of differentiating human Th17 cells. Wilson et al., 2007; Acosta-Rodriguez et al, 8 Nature Immunol. 942-49 (2007). It has been suggested that TGF-β may, in fact, suppress the generation of human Th17 cells. Evans et al., 104 P.N.A.S. 17034-39 (2007). Instead, it has recently been shown that the cytokines IL-1β, IL-6, and IL-23 are capable of driving IL-17 secretion in short-term CD4+ T cell lines isolated from human peripheral blood (Laurence & Shea, 8 Nature Immunol. 903-05 (2007)), though the factors required for differentiation of naïve human CD4 to Th17 cells remained unknown until the present invention. The present invention provides that although IL-1β and IL-6 induce IL-17A secretion from human central memory CD4+ T cells, TGF-β and IL-21 uniquely promote the differentiation of human naïve CD4+ T cells into Th17 cells, accompanied by expression of RORC2. The present invention will now facilitate the investigation of the role played by the population of Th17 cells in human inflammatory disease.
- Better understanding of the regulation of IL-17A secretion from human CD4+ T cells required a strategy that would allow the evaluation of the effects of various cytokine combinations on expansion of IL-17-expressing cells from memory T cells, versus differentiation of naïve CD4 lymphocytes into Th17 cells. Specifically, high-speed flow cytometry was used to sort these two distinct populations of CD4+ T cells from the peripheral blood of healthy subjects: CD4+ CD25− CD62L+ CD45RAhi cells highly enriched for naïve T cells and CD4+ CD25− CD62L+ CD45RA− cells enriched for central memory T cells (Tcm) (
FIG. 1A ). The cells enriched for a naïve phenotype were uniformly positive for CCR7 expression. These two T cell populations were then stimulated with plate-bound anti-CD3 and soluble anti-CD28 monoclonal antibodies for seven days in serum-free medium containing different combinations of cytokines implicated in CD4+ T cell differentiation. As previously reported, the cytokine interleukin-β induced the greatest amount of IL-17A secretion from Tcm (FIG. 1B ). The addition of IL-6 alone had little effect on induction of IL-17A, and when added with IL-1β had no additive or synergistic effect on IL-17A production. Addition of IL-23 was also able to modestly enhance IL-17A secretion from Tcm. IL-1β either alone or together with IL-6 failed, however, to induce IL-17A secretion from naïve CD4+ T cells. - In marked contrast, a combination of TGF-β and IL-21 was uniquely able to induce Th17 differentiation. Whereas IL-21, IL-1β, or IL-6 induced significant amounts of IFN-β secretion from naïve T cells, the addition of TGF-β with IL-21 suppressed IFN-β secretion and induced differentiation of Th17 cells. Intracytoplasmic staining demonstrated, in agreement with ELISA results, that the combination of TGF-β and IL-21 differentiated CD4+ T cells that secreted only IL-17A and no IFN-β (
FIG. 1C ). When starting with FACS-isolated naïve CD4+ T cells, between 10%-15% of CD4+ T cells secrete IL-17A after just seven days of differentiation. - In the murine model, Th17 differentiation coincides with expression of murine RORγt, a transcription factor critical for the differentiation of murine IL-17-secreting T cells. RORC2 is the human homologue of murine RORγt, thus, quantitative RT-PCR was used to evaluate mRNA levels of RORC2 and other molecules implicated in Th17 differentiation. The combination of TGF-β and IL-21 induced high levels of RORC2 (
FIG. 2A ), consistent with their ability to induce IL-17A secretion from naïve human CD4+ T cells. It was of particular interest that the combination of TGF-β and IL-6 that induces Th17 differentiation in murine T cells also induced expression of RORC2 in naïve human CD4 cells. As this combination of cytokines did not, however, induce IL-17A secretion, these data indicate that expression of RORC2 in humans is not in itself sufficient to induce IL-17 production and another as yet unidentified transcription factor in combination with RORC2 may be required to induce IL-17A-secreting Th17 cells. - Additional transcription factors implicated in Th1 and Th2 cell differentiation were also examined: T-bet is the master regulator for IFN-γ secreting Th1 cells, and GATA-3 induces IL-4 secreting Th2 cells. mRNA expression levels of T-bet were highly concordant with amounts of IFN-γ secretion and were consistent with findings that although TGF-β and IL-21 induce Th17 cell differentiation with RORC2 expression, TGF-β suppresses the induction of T-bet by IL-21. Similarly, there was no induction of GATA-3 with TGF-β and IL-21. The cytokines IL-6, IL-21 and IL-1β, but not TGF-β, induced IL-23 receptor up-regulation in stimulated naïve CD4+ T cells. The expression of the Treg transcription factor FoxP3 was also examined. As has been previously reported in both murine and human systems, FoxP3 was induced by TGF-β. This induction of FoxP3 was inhibited by both IL-6 and to a greater extent IL-21, transcription factors that induce RORC2. Thus, although the induction of RORC2 and FoxP3 transcription factors was highly similar between murine and human naïve CD4 cells, the induction of IL-17A by IL-6 in combination with TGF-β is discordant between the species.
- It was shown previously that IL-21 secreted by murine CD4+ T cells can induce the secretion of IL-21 in an autocrine loop. Korn et al., 2007; Nurieva et al., 2007; Zhou et al., 2007; Weo et al., 282 J. Biol. Chem. 34605-10 (2007). Thus, whether human IL-21 induced IL-21 secretion from naïve CD4+ T cells was evaluated, as were the effects of a combination of TGF-β with IL-21 and IL-1β, given the ability of these cytokines to induce IL-17 from naïve and central memory CD4+ T cells. Consistent with results observed in mice, IL-21 significantly up-regulated IL-21, though IL-1β induced even greater amounts of IL-21 mRNA (
FIG. 2B ). In contrast to what has been observed in mice, however, IL-21 also induced IL-22 mRNA levels in naïve CD4+ T cells in the absence of any exogenous IL-23. TGF-β, in contrast, suppressed the expression of IL-21 and IL-22 mRNA induced by IL-21 (FIG. 2B ). These data further highlight differences between the CD4+ T cells of mice and men: although IL-21 induces IL-21 and IL-22, the T cell differentiation to Th17 cells with TGF-β inhibits the expression of these cytokines - The unique function of TGF-β and IL-21 in the differentiation of Th17 cells from naïve human CD4+ T cells was confirmed by sorting CD4+ CD25− CD62L+ CD45RAhi cells from human cord blood. A higher proportion of CD4 cells in the cord blood exhibited this naïve phenotype relative to peripheral blood obtained from healthy adult subjects. Although it was difficult to detect IL-17A secretion from stimulated naïve cord blood T cells, TGF-β and IL-21 induced the up-regulation of IL-17A and RORC2 mRNA (
FIG. 2C ). Additionally, although IL-21 alone modestly induced RORC2, only TGF-β and IL-21 were able to induce IL-17A mRNA. These data further indicate that TGF-β and IL-21 are critical in the differentiation of both human and murine Th17 cells. - The present invention refines and extends the understanding of the regulation of IL-17A secretion from human CD4+ T cells, and defines the conditions required for human Th17 cell differentiation. IL-1β together with IL-6 or IL-23 can induce IL-17A secretion, but these cytokines induce IL-17A expression from human memory CD4+ T cells and not from human naïve CD4+ T cells. TGF-β and IL-21, in combination, is required for the differentiation of Th17 cells from human naïve T cells.
- The explanation for disparate results reported previously in the literature may be due to either the failure to obtain sufficiently pure naïve T cells using magnetic bead isolation, or use of medium containing human serum which is known to contain substantial amounts of both IL-6 and TGF-β (Wilson et al., 2007), and the use of neutralizing antibodies against both IFN-β and IL-4 in addition to the cytokines listed above. Acosta-Rodriguez et al., 2007.
- The present work suggests that the IL-1β and IL-6 induced during the early stages of an inflammatory response may act on memory T cells to promote IL-17 and IL-21 secretion, with induced IL-21 able to synergize with TGF-β to promote differentiation of Th17 cells from naïve CD4+ T cells. The general immunosuppressive properties of TGF-β may be responsible for suppression of IFN-γ induced by IL-21 or IL-6. Nevertheless, the simple lack of IFN-γ is not sufficient to promote Th17 differentiation from naïve CD4+ T cells as Th17 differentiation was not achieved with a combination of TGF-β and IL-6 when IFN-γ secretion was well-suppressed. A wide range of doses of TGF-β were examined, ranging from 1 ng/ml to 100 ng/ml, and, indeed, at high doses of TGF-β all differentiation/proliferation was suppressed. The FACS sorted naïve CD4+ T cells from both adult and cord blood, had little to no detectable FoxP3 expression. Moreover, IL-21 alone does not induce human Th17 differentiation, which requires the presence of TGF-β. Thus, these data indicate that IL-21 does not promote Th17 differentiation simply by suppressing TREG activity. Further, although it is possible that T cells may produce sufficient amounts of TGF-β to synergize with IL-21 to promote Th17 differentiation, the naïve CD4+ T cells represented herein did not produce sufficient amounts, as the addition of IL-21 alone was unable to synergize with endogenous levels of TGF-β to promote IL-17 secretion.
- Ultimately, the experimental approach simultaneously comparing both naïve and memory cell populations in response to cytokine combinations allows the more definitive statements about the cell populations that respond to particular cytokines, as examined by others: that IL-1β and IL-6 induce IL-17 secretion from memory CD4+ T cells, and that TGF-β and IL-21 induce the differentiation of IL-17-secreting CD4+ T cells from naïve CD4+ T cells. The present invention now allows for the characterization of human inflammatory Th17 responses associated with infection and autoimmune diseases.
- Thus, the present embodiments relate to methods and compositions for modulating Th17 cell differentiation and activity. The methods and compositions, e.g., agonists or antagonists of TGF-β and IL-21, described herein are useful in treating (e.g., curing, ameliorating, delaying or preventing the onset of, or preventing recurrence or relapse of), or preventing immune-associated ailments such as asthma, allergy, rheumatoid arthritis, multiple sclerosis, lupus, type I diabetes, Crohn's disease, psoriasis, myasthenia gravis, or other autoimmune disorders associated with Th17 differentiation.
- In one embodiment, the method includes contacting a human T cell or human T cell population with TGF-β and IL-21 agonists in amount sufficient to induce differentiation of the T cell or T cell population into a Th17 cell or a Th17 cell population. Hence, a method of increasing Th17 cell activity and/or Th17 cell number is provided. For example, Th17 cell activity and/or cell number can be increased by increasing differentiation (e.g., differentiation of a naïve T cell) into a Th17 cell. The method includes (optionally) identifying a cell (a T cell), or a cell population, where increased differentiation is desired, and contacting said cell or cell population with a TGF-β/IL-21 agonists in an amount sufficient to increase differentiation into Th17 cells, thereby increasing Th17 cell activity and/or cell number.
- In a related embodiment, the contacting step is carried out ex vivo, in vitro, or in vivo. In some embodiments, the contacting step is performed using mammalian or human cells, or performed in a patient such as a human patient. For example, immune cells, e.g., T cells as described herein, can be cultured in vitro in culture medium and the contacting step can be effected by adding one or more TGF-β/IL-21 modulators (TGF-β/IL-21 agonists or antagonists), to the culture medium. Alternatively, the method is performed on cells (such as immune or T cells) present in a subject as part of an in vivo (e.g., therapeutic or prophylactic) protocol.
- The TGF-β agonist can be a TGF-β polypeptide, a human TGF-β polypeptide, or an active fragment thereof (e.g., a recombinant human TGF-β polypeptide or its encoding nucleic acid). The TGF-β agonist may be a fusion protein comprising an TGF-β polypeptide, e.g., human TGF-β polypeptide, or a fragment thereof fused to another polypeptide, e.g., an immunoglobulin polypeptide or a portion thereof (e.g., a Fc region of an immunoglobulin polypeptide); an agonist antibody to the TGF-β receptor TGF-βR); or a small molecule agonist. Human recombinant TGF-βs are available commercially (e.g., from Bioclone, Inc., San Diego, Calif., and R&D Systems, Minneapolis, Minn.). Reconstitution and transphosphorylation of recombinant TGF-βR complexes has also been reported. Ventura et al., 13(23) EMBO J. 5581-89 (1994). TGF-β expression may also be up-regulated using other cytokines, such as TNF-α. Sullivan et al., AJRCMB (Jan. 14, 2005).
- The IL-21 agonist can be an IL-21 polypeptide, a human IL-21 polypeptide, or an active fragment thereof (e.g., a recombinant human IL-21 polypeptide or its encoding nucleic acid). The IL-21 agonist may be a fusion protein comprising an IL-21 polypeptide, e.g., human IL-21 polypeptide, or a fragment thereof fused to another polypeptide, e.g., an immunoglobulin polypeptide or a portion thereof (e.g., a Fc region of an immunoglobulin polypeptide); an agonist antibody to the IL-21 receptor IL-21R); or a small molecule agonist. Recombinant human IL-21 is available commercially, e.g., from Prospec Protein Specialists (Rehovot, Israel). Additionally, the nucleotide sequence and amino acid sequence of a human IL-21 is available at Genbank Acc. No. X_011082. Murine IL-21 polypeptides and nucleic acids encoding such polypeptides are exemplified in WO/2004/007682. In other embodiments, the IL-21 agonist is an agent that increases the activity or level of IL-21 by, e.g., increasing expression, processing and/or secretion of functional IL-21.
- In another embodiment, the invention provides for a method for inhibiting precursor T cell or T cell population differentiation into a Th17 cell or Th17 cell population. The method includes contacting the T cell or T cell population with an antagonist of a TGF-β and IL-21, or a TGF-βR and IL-21R, in amounts sufficient to inhibit Th17 cell differentiation. The TGF-β antagonist may be, for example, an anti-TGF-βR antibody, an antigen-binding fragment of an anti-TGF-βR antibody, or a soluble fragment of an TGF-βR. The IL-21 antagonist may be, for example, an anti-IL21R antibody, an antigen-binding fragment of an anti-IL21R antibody, or a soluble fragment of an IL-21R. Expression of TGF-β and IL-21 or their receptor genes may be suppress by RNA interference with, e.g., dsRNA, ssRNA, siRNA, miRNA, artificial derivatives of the forgoing, and the like.
- TGF-β and IL-21 antagonists that inhibit a TGF-β/IL-21 mediated T helper cell effect, an agent that blocks or otherwise inhibits the interaction of TGF-β to a TGF-βR or IL-21 to an IL-21R can be added to a T cell or a population of T cells. These antagonists include, e.g., soluble fragments of TGF-β or IL-21 polypeptide, TGF-βR or IL-21R fragments, fusion proteins containing these fragments, and antibodies to these fragments.
- Antibodies include all such classes, subclasses and types of human antibody species. For example, antibodies to TGF-β or TGF-βR polypeptides also include antibodies to fusion proteins containing TGF-β or TGF-βR polypeptides or fragments of TGF-β or TGF-βR polypeptides. Similarly, antibodies to IL-21 or IL-21R polypeptides also include antibodies to fusion proteins containing IL-21 or IL-21R polypeptides or fragments of IL-21 or IL-21R polypeptides.
- More specifically, the TGF-β antagonist can be, e.g., an antibody (e.g., a monoclonal or single specificity antibody) to TGF-β or human TGF-β, or a TGF-βR polypeptide. The antibody may be human, humanized, chimeric, or in vitro generated antibody to human TGF-β or human TGF-βR polypeptides. In other embodiments, the antagonist includes a fragment of a TGF-β polypeptide, e.g., a TGF-β binding domain of a TGF-β polypeptide. Alternatively, the antagonist includes a fragment of a TGF-βR polypeptide, e.g., a TGF-β binding domain of a TGF-βR polypeptide. In one embodiment, the antagonist is a fusion protein comprising the aforesaid TGF-β or TGF-βR polypeptides or fragments thereof fused to a second moiety, e.g., a polypeptide (such as an immunoglobulin chain). Anti-TGF-β antibodies are available commercially, e.g., from Invitrogen Corp. (Carlsbad, Calif.), as are numerous antibodies targeting proteins involved in TGF-β signaling pathways. Agents that inhibit endogenous TGF-β include pirfenidone (Liu et al., 5 Am. J. Transplantation, 1266-63 (2005), or other compounds such as those described in U.S. Pat. No. 7,314,939. Agents that inhibit TGB-beta signaling, include Halofuginone (Figueiro-Ponts et al., 92(2) Haematologica 177 (2007)), Genistein, and curcumin (Santibanez et al., 37(1) Nutrition & Cancer, 49-54 (2000)).
- Additional TGF-β Superfamily modulators include Amnionless NCAM-1/CD56, BAMBI/NMA Noggin, BMP-1PCP NOMO, Caronte PRDC,
Cerberus 1 SKI, Chordin Smad1, Chordin-Like 1 Smad2, Chordin-Like 2 Smad3, COCO Smad4, CRIM1 Smad5, Cripto Smad7, Crossveinless-2 Smad8, Cryptic SOST/Sclerostin, DAN Latent TGF-β bp1, Decorin Latent TGF-β bp2, Dermatopontin Latent TGF-β bp4, FLRG TMEFF1/Tomoregulin-1, Follistatin TMEFF2, Follistatin-like 1 TSG, GASP-1/WFIKKNRP TSK, GASP-2/WFIKKN Vasorin, Gremlin, from R&D Systems (Minneapolis, Minn.). - The IL-21 antagonist can be, e.g., an antibody (e.g., a monoclonal or single specificity antibody) to IL-21 or human IL-21, or an IL-21R polypeptide. The antibody may be human, humanized, chimeric, or in vitro generated antibody to human IL-21 or human IL-21R polypeptides. In other embodiments, the antagonist includes a fragment of an IL-21 polypeptide, e.g., an IL-21R binding domain of an IL-21 polypeptide. Alternatively, the antagonist includes a fragment of an IL-21R polypeptide, e.g., an IL-21 binding domain of an IL-21R polypeptide. In one embodiment, the antagonist is a fusion protein comprising the aforesaid IL-21 or Il-21R polypeptides or fragments thereof fused to a second moiety, e.g., a polypeptide (such as an immunoglobulin chain).
- For example, IL-21 modulators available commercially include human IL-21R, recombinant human IL-21R/Fc chimera, human IL-21R Allophycocyanin MAb, human IL-21R Biotinylated PAb, human IL-21R MAb, and human IL-21R Phycoerythrin MAb, from R&D Systems (Minneapolis, Minn.). Other agents may serve as antagonists of IL-21 gene expression. For example, cyclosporine inhibits the IL-21 promoter. Kim et al., 280 (26) J. Biol. Chem. (2005). Other IL-21 antagonists are reported in U.S. Pat. No. 7,186,805 and No. 6,929,932, relating to IL-21 mutants that bind IL-21R.
- In another embodiment, the invention features a method for modulating, e.g., increasing, or reducing or inhibiting, the activity or level of cytokines, such as IFN-γ or IL-17, in human a T cell or human T cell population. For example, a method for modulating one or more of: IL-17 activity, expression, secretion, or processing, in a T cell or a Th17 cell, or a cell population thereof, is provided. The method includes: (optionally) identifying a cell in which modulation (increase or reduction) of the activity or level of IL-17 is desired; and contacting said cell or cell population with an amount of TGF-β/IL-21 modulators, e.g., TGF-β/IL-21 agonists or antagonists, sufficient to modulate the activity or level of IL-17 in said cell or cell population. As noted, the contacting step may be carried out ex vivo, in vitro, or in vivo. For example, the contacting step may be performed using human cells, or performed in a human patient.
- Notably, the TGF-β/IL-21 modulators discussed herein may specifically inhibit IL-17 levels or activity, but may also reduce or inhibit the activity or level of other cytokines associated with IL-17 expression or Th17 functionality. For example, the TGF-β/IL-21 agonists inhibit production of IFN-γ by an IFN-γ -producing cell such as a Th1 cell.
- The TGF-β polypeptide or TGF-βR polypeptide moiety may be variant TGF-β or TGF-βR polypeptide having mutations in the naturally-occurring TGF-β or TGF-βR sequence (wild type) that results in an TGF-β or TGF-βR sequence more resistant to proteolysis (relative to the non-mutated sequence). Likewise, the IL-21 polypeptide or IL-21R polypeptide moiety may be a variant IL-21 or IL-21R polypeptide having mutations in the naturally-occurring IL-21 or IL-21R sequence (wild type) that results in an IL-21 or IL-21R sequence more resistant to proteolysis (relative to the non-mutated sequence).
- TGF-β, TGF-βR, IL-21 and IL-21R, or active fragments of these proteins, can be fused to carrier molecules such as immunoglobulins for use in the herein described methods. For example, soluble forms of the receptor may be fused through “linker” sequences to the Fc portion of an immunoglobulin or to the Fc portion of the immunoglobulin. Other fusions proteins, such as those with glutathione S-transferase (GST), LexA, or maltose binding protein (MBP), may also be used.
- In a further embodiment, TGF-β, TGF-βR, IL-21 or IL-21R fusion protein may be linked to one or more additional moieties. For example, the fusion protein may additionally be linked to a GST fusion protein in which the fusion protein sequences are fused to the C-terminus of the GST sequences. Such fusion proteins can facilitate the purification of the TGF-β, TGF-βR, IL-21 or IL-21R fusion proteins.
- In another embodiment, the fusion protein includes a heterologous signal sequence (i.e., a polypeptide sequence that is not present in a polypeptide naturally encoded by TGF-β, TGF-βR, IL-21 or IL-21R nucleic acid) at its N-terminus. For example, the native signal sequence can be removed and replaced with a signal sequence from another protein.
- A chimeric or fusion protein of the invention can be produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different polypeptide sequences are ligated together in-frame in accordance with conventional techniques, e.g., by employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers.
- As noted, the methods described herein may be used on cells, e.g., T cells, in vitro or ex vivo. Alternatively, the method can be performed on cells present in a subject as part of an in vivo (e.g., therapeutic or prophylactic) protocol. For example, the method can be used to treat or prevent a Th17-mediated disorder in a subject. Accordingly, the invention provides a method of treating (e.g., curing, suppressing, ameliorating, delaying or preventing the onset of, or preventing recurrence or relapse of) or preventing a Th17-associated disorder in a subject. The method includes administering to a subject a TGF-β/IL-21 antagonists in an amount sufficient to inhibit or reduce Th17 cell activity and/or cell number, thereby treating or preventing a Th17-associated disorder.
- The subject is a mammal, such as a human suffering from a disorder associated with aberrant Th17 cell number or activity, e.g., an immune disorder. The amount sufficient to inhibit or reduce the Th17 cell activity and/or Th17 cell number is an amount sufficient to ameliorate or prevent said disorder.
- The TGF-β/IL-21 modulators effective in the present invention, more particularly the chemical agents or compounds that serve as agonists or antagonists, include pro-drugs. The term “pro-drug” refers to any compound which releases an active parent drug in vivo when such pro-drug is administered to a mammalian subject. Pro-drugs of a compound are typically prepared by modifying one or more functional group(s) present in the compound in such a way that the modification(s) may be cleaved in vivo to release the parent compound. Examples of pro-drugs include, but are not limited to, esters (e.g., acetate, formate, and benzoate derivatives) and carbamates (e.g., N,N-dimethylaminocarbonyl) of hydroxy functional groups, and amides, carbamates and urea derivatives of amino functional groups, and the like. Pro-drug forms often offer advantages of solubility, tissue compatibility, or delayed release in the mammalian organism. See Bundgard, DESIGN OF PRODRUGS, 7-9, 21-24 (Elsevier, Amsterdam, 1985); Silverman, ORGANIC CHEM. OF DRUG DESIGN & DRUG ACTION, 352-401 (Academic Press, San Diego, Calif.). Moreover, the prodrug derivatives of the invention may be combined with other features known to one skilled in the art to enhance bioavailability.
- The TGF-β/IL-21 modulators described herein can be conveniently provided in pharmaceutical compositions. The compositions may be suitable for internal use and include an effective amount of the pharmacologically active compounds of the invention, alone or in combination, with one or more pharmaceutically acceptable carriers. The compounds are especially useful in that they have very low, if any toxicity. In practice, the compounds or their pharmaceutically acceptable salts, are administered in amounts which will be sufficient to effect the desired change, such as an increase or decrease Th17 cell differentiation, and are used in the pharmaceutical form most suitable for such purposes.
- For pharmaceutical use, the proteins of the present invention are formulated for parenteral, particularly intravenous or subcutaneous, delivery according to conventional methods. The bioactive polypeptide or antibody conjugates described herein can be delivered intravenously, intraarterially or intraductally, or may be introduced locally at the intended site of action. Intravenous administration will be by bolus injection or infusion over a typical period of one to several hours. In general, pharmaceutical formulations will include a IL-21 protein in combination with a pharmaceutically acceptable vehicle, such as saline, buffered saline, 5% dextrose in water or the like. Formulations may further include one or more excipients, preservatives, solubilizers, buffering agents, albumin to prevent protein loss on vial surfaces, etc. Methods of formulation are well known in the art and are disclosed, for example, in REMINGTON: SCI. & PRACTICE OF PHARMACY (Gennaro, ed., Mack Pub. Co., Easton, Pa., 19th ed., 1995). Therapeutic doses may generally be in the range of 0.1 μg/kg to 100 μg/kg of patient weight per day, such as 0.5 μg/kg-20 μg/kg per day, with the exact dose determined by the clinician according to accepted standards, taking into account the nature and severity of the condition to be treated, patient traits, etc. Determination of dose is within the level of ordinary skill in the art. The proteins may be administered for acute treatment, over one week or less, often over a period of one to three days or may be used in chronic treatment, over several months or years. In general, a therapeutically effective amount of the TGF-β/IL-21 modulators is an amount sufficient to produce a clinically significant change in hematopoietic or immune function
- For instance, for oral administration in the form of a tablet or capsule (e.g., a gelatin capsule), the active drug component can be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like. Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents and coloring agents can also be incorporated into the mixture. Suitable binders include starch, magnesium aluminum silicate, starch paste, gelatin, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, polyethylene glycol, waxes and the like. Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, silica, talcum, stearic acid, its magnesium or calcium salt and/or polyethyleneglycol and the like. Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum starches, agar, alginic acid or its sodium salt, or effervescent mixtures, and the like. Diluents, include, e.g., lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycine.
- Injectable compositions are preferably aqueous isotonic solutions or suspensions, and suppositories are advantageously prepared from fatty emulsions or suspensions. The compositions may be sterilized and/or contain adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and/or buffers. In addition, they may also contain other therapeutically valuable substances. The compositions are prepared according to conventional mixing, granulating or coating methods, respectively, and contain about 0.1% to 75%, such as about 1% to 50%, of the active ingredient. More specifically, any of the pharmaceutical compositions discussed herein may contain 0.1% to 99%, such as 1% to 70% of the TGF-β/IL-21, TGF-βR/IL-21R, TGF-β/IL-21 agonists, or TGF-β/IL-21 antagonists.
- The compounds of the invention can also be administered in such oral dosage forms as timed release and sustained release tablets or capsules, pills, powders, granules, elixers, tinctures, suspensions, syrups and emulsions.
- Liquid, particularly injectable compositions can, for example, be prepared by dissolving, dispersing, etc. The active compound is dissolved in or mixed with a pharmaceutically pure solvent such as, for example, water, saline, aqueous dextrose, glycerol, ethanol, and the like, to thereby form the injectable solution or suspension. Additionally, solid forms suitable for dissolving in liquid prior to injection can be formulated. Injectable compositions are preferably aqueous isotonic solutions or suspensions. The compositions may be sterilized and/or contain adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and/or buffers. In addition, they may also contain other therapeutically valuable substances.
- The compounds of the invention can be administered in intravenous (both bolus and infusion), intraperitoneal, subcutaneous or intramuscular form, all using forms well known to those of ordinary skill in the pharmaceutical arts. Injectables can be prepared in conventional forms, either as liquid solutions or suspensions.
- Parenteral injectable administration is generally used for subcutaneous, intramuscular or intravenous injections and infusions. Additionally, one approach for parenteral administration employs the implantation of a slow-release or sustained-released systems, which assures that a constant level of dosage is maintained, according to U.S. Pat. No. 3,710,795.
- Furthermore, compounds for the invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in that art. To be administered in the form of a transdermal delivery system, the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen. Other preferred topical preparations include creams, ointments, lotions, aerosol sprays and gels, wherein the concentration of active ingredient would range from 0.1% to 15%, w/w or w/v.
- For solid compositions, excipients include pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium carbonate, and the like may be used. The active compound defined above, may be also formulated as suppositories using for example, polyalkylene glycols, for example, propylene glycol, as the carrier. In some embodiments, suppositories are advantageously prepared from fatty emulsions or suspensions.
- The compounds of the invention can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, containing cholesterol, stearylamine or phosphatidylcholines. In some embodiments, a film of lipid components is hydrated with an aqueous solution of drug to a form lipid layer encapsulating the drug, as described in U.S. Pat. No. 5,262,564.
- Compounds of the invention may also be delivered by the use of monoclonal antibodies as individual carriers to which the compound molecules are coupled. The compounds of the invention may also be coupled with soluble polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropyl-methacrylamide-phenol, polyhydroxyethylaspanamidephenol, or polyethyleneoxidepolylysine substituted with palmitoyl residues. Furthermore, the compounds of the invention may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross-linked or amphipathic block copolymers of hydrogels.
- Alternatively, where the complete gene delivery vector can be produced intact from recombinant cells, e.g., retroviral vectors, the pharmaceutical preparation can include one or more cells that produce the gene delivery system.
- If desired, the pharmaceutical composition to be administered may also contain minor amounts of non-toxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents, and other substances such as for example, sodium acetate, triethanolamine oleate, etc.
- The dosage regimen utilizing the compounds is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular compound or salt thereof employed. An ordinarily skilled physician or veterinarian can readily determine and prescribe the effective amount of the drug required to prevent, counter or arrest the progress of the condition.
- Oral dosages of the invention, when used for the indicated effects, will range between about 0.05 mg/day to 1000 mg/day orally. Effective plasma levels of the compounds of the invention range from 0.002 mg to 50 mg per kg of body weight per day. Compounds of the invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three or four times daily.
- A further embodiment of the present invention provides for a method for modulating the activity of a Th17 cell or Th17 cell population comprising contacting said cell or cell population with an amount of Th17 activity modulator sufficient to modulate the activity of a Th17 cell or Th17 cell population. For example, the migration activity of Th17 cells may be inhibited by U75-302, an antagonist of the Th17-specific leukotriene B4. Similarly, the migration activity of Th17 cells may be inhibited by podoplanin. Such Th17-activity-specific modulators may be formulated according to the foregoing discussions for use in vitro and in vivo.
- The present invention also provides for the identification of Th17 cells via cell surface molecules that are specifically up-regulated in Th17 cells. More specifically, expression profiling comparing naïve T cells differentiated into Th17 cells with T cells cultured in the presence of either IL-6 alone or TGF-β alone identified genes expressed specifically in Th17 cells (differentiated in the presence of TGF-β plus IL-6) but not in naïve T cells activated in the presence of IL-6, TGF-β, or no cytokines Consistent with published literature, IL-17A and the transcription factors RORγt and RORα were up-regulated in Th17 cells compared to cells cultured in other conditions. Ivanov et al., 126 Cell 1121-33 (2006); Yang et al., Immunity (2007). Two surface molecules: BLT1 (LTB4R1) (the receptor for the leukotriene B4), and podoplanin are specifically up-regulated in Th17 cells (
FIG. 6 ). - Using the markers of the present invention, Th17 cells may be identified in a sample. The “sample” or “biological sample” may be any biological material taken either directly from a subject human being (or animal), or after culturing (enrichment). Biological material may include expectorations of any kind, broncheolavages, blood, skin tissue, biopsies, semen, lymphocyte blood culture material, colonies, liquid cultures, faecal samples, urine, etc. Biological material may also include cell cultures or the liquid phase thereof The term “biological sample” generally refers to any biological sample (tissue or fluid) containing Th17 cells, and includes blood serum or plasma samples.
- The sample may be collected from a subject, which refers to an individual regardless of health and/or disease status. A subject can be a patient, a study participant, a control subject, a screening subject, or any other class of individual from whom a sample is obtained and assessed in the context of the invention. A subject can be diagnosed with a disease, can present with one or more symptom of a disease, or a predisposing factor, such as a family (genetic) or medical history (medical) factor, for a disease. Alternatively, a subject can be healthy with respect to any of the aforementioned factors or criteria, although the term “healthy” is relative to a specified disease, or disease factor, or disease criterion, and can not be defined to correspond to any absolute evaluation or status. Thus, an individual defined as healthy with reference to any specified disease or disease criterion, can in fact be diagnosed with any other one or more disease, or exhibit any other one or more disease criterion.
- Additionally, although the discussion of the invention focuses on, and is exemplified using human and murine cells and markers, the particular markers may be applicable to other non-human animals and have use in research and veterinary practice.
- The Th17 cell-specific markers of the present invention can be identified by antibodies. Such antibodies can include, but are not limited to polyclonal antibodies, monoclonal antibodies (mAbs), humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab′)2 fragments, fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies, and epitope-binding fragments of any of the above. Such antibodies can be used, for example, in the detection Th17 markers in a biological sample, or, alternatively, as a modulator to Th17 functionality as described herein. Thus, such antibodies can be utilized as part of autoimmune or other disease treatment methods, and/or can be used as part of diagnostic techniques whereby patients may be tested for abnormal levels of Th17-specific markers.
- A number of protocols for carrying out immunoassays are known, which can, for example, be based upon competition, or direct reaction, or sandwich assays. Protocols can use solid supports or immunoprecipitation. Immunoassays generally involve the use of labeled antibody or polypeptide. The labels can be, for example, fluorescent, chemiluminescent, radioactive, or dye molecules. A particular aspect of the invention provides for molecules capable of recognizing podoplanin and/or BLT1, attached to a substrate.
- The markers of the present invention can also be identified by assessing their expression via nucleic acid molecules. Numerous methods for obtaining expression data are known, and any one or more of these techniques, singly or in combination, are suitable for determining expression profiles in the context of the present invention. For example, expression patterns can be evaluated by northern analysis, PCR, RT-PCR, Taq Man analysis, FRET detection, monitoring one or more molecular beacons, hybridization to an oligonucleotide array, hybridization to a cDNA array, hybridization to a polynucleotide array, hybridization to a liquid microarray, hybridization to a microelectric array, cDNA sequencing, clone hybridization, cDNA fragment fingerprinting, serial analysis of gene expression (SAGE), subtractive hybridization, differential display and/or differential screening. See, e.g., Lockhart & Winzeler 405 Nature 827-36 (2000); U.S. Pat. No. 6,905,827.
- The present invention also provides a kit for the identification of Th17 cells. Typically, a kit contains one or more probes, such as antibodies or diagnostic nucleotides. The probe can exist as part of a diagnostic nucleotide probe set, or other subset of a candidate library, (e.g., as a cDNA, oligonucleotide, or antibody microarray or reagents for performing an assay on a diagnostic gene set using any expression profiling technology), packaged in a suitable container. The kit can further comprise, one or more additional reagents, e.g., substrates, labels, primers, for labeling expression products, tubes and/or other accessories, reagents for collecting blood samples, buffers, e.g., erythrocyte lysis buffer, leukocyte lysis buffer, hybridization chambers, cover slips, etc., as well as a software package, e.g., including the statistical methods of the invention, e.g., as described above, and a password and/or account number for accessing the compiled database. The kit optionally further comprises an instruction set or user manual detailing preferred methods of using the diagnostic probes in the methods of the invention.
- The methods and kits for identifying Th17 cells can be used to identify or determine (qualitatively or quantitatively) if a subject (e.g., and patient or individual) has Th17 cells. In some instances, Th17 cells may be associated with an autoimmune disorder. An autoimmune disorder is defined as a disease state in which a patient's immune system recognizes an antigen in that patient's organs or tissues as foreign and becomes activated. The activated immune cells can then cause damage to the inciting organ or tissue or can damage other organs or tissues. In some cases, the disorder may be caused by a dysregulation of the immune system cells, rather than by the recognition as a self-antigen as foreign. Dysregulated immune cells can secrete inflammatory cytokines that cause systemic inflammation or they can recognize self-antigens as foreign.
- Examples of autoimmune diseases include autoimmune hepatitis, multiple sclerosis, myasthenia gravis, Type I diabetes, rheumatoid arthritis, psoriasis, systemic lupus erythematosis, Hashimoto's thyroiditis, Grave's disease, ankylosing spondylitis Sjogrens disease, CREST syndrome, and scleroderma. Most of the autoimmune diseases are also chronic inflammatory diseases. This is defined as a disease process associated with long-term (>6 months) activation of inflammatory cells (leukocytes). The chronic inflammation leads to damage of patient organs or tissues. Many diseases are chronic inflammatory disorders, but are not know to have an autoimmune basis. Examples include atherosclerosis, congestive heart failure, Crohn's disease, ulcerative colitis, polyarteritis nodosa, Whipple's Disease, and primary sclerosing cholangitis.
- The identification of Th17 cells can be useful in monitoring individuals with autoimmune disorders. Monitoring describes the observation of Th17 cell markers to provide useful information about an individual or an individual's health or disease status. “Monitoring” can include determination of prognosis, risk-stratification, selection of drug therapy, assessment of ongoing drug therapy, prediction of outcomes, determining response to therapy, diagnosis of a disease or disease complication, following progression of a disease or providing any information relating to a patients health status.
- Further regarding rheumatoid arthritis (RA), the Th17-specific cell surface molecules of the present invention can be used in the diagnosis and monitoring of RA. RA effects about two million patients in the U.S. and is a chronic and debilitating inflammatory arthritis, particularly involving pain and destruction of the joints. RA often goes undiagnosed because patients may have no pain, but the disease is actively destroying the joint. Other patients are known to have RA, and are treated to alleviate symptoms, but the rate of progression of joint destruction is not monitored easily. Drug therapy is available, but the most effective medicines are toxic (e.g., steroids, methotrexate) and should be used with caution. A new class of medications, TNF blockers, is effective, but the drugs are expensive, have side effects, and not all patients respond.
- RA disease criteria correspond to disease symptoms (e.g., joint pain, joint swelling and joint stiffness and any of the American College for Rheumatology criteria for the diagnosis of RA, see Arnett et al., 31 Arthr. Rheum. 315-24 (1988), progression of joint destruction (e.g., as measured by serial hand radiographs, assessment of joint function and mobility), surgery, need for medication, additional diagnoses of inflammatory and non-inflammatory conditions, and clinical laboratory measurements including complete blood counts with differentials, CRP, ESR, ANA, Serum IL6, Soluble CD40 ligand, LDL, HDL, Anti-DNA antibodies, rheumatoid factor, C3, C4, serum creatinine, death, hospitalization, and disability due to joint destruction. In addition, or alternatively, disease criteria correspond to response to drug therapy and presence or absence of side-effects or measures of improvement exemplified by the American College of Rheumatology “20%” and “50%” response/improvement rates. See Felson et al., 38 Arthr. Rheum. 531-37 (1995). The Th17 markers of the instant invention identify, monitor, and predict disease progression including flaring (acute worsening of disease accompanied by joint pain or other symptoms), response to drug treatment and likelihood of side-effects.
- In conclusion, Th17 cells are potent inducers of inflammation and autoimmune diseases. Th17 cells are found in the target organs of many autoimmune diseases. Until the present invention, however, the absence of known markers on surface of these cells has not allowed the detection and isolation of live Th17 cells from tissues and therefore the characterization of their effector function during autoimmune diseases. The identification of molecules such as BLT1 and podoplanin, specifically expressed on the surface of Th17 cells, will greatly aid basic research regarding these cells, and diagnosis of Th17-associated illness such as multiple sclerosis, psoriasis, rheumatoid arthritis and Crohn's disease.
- The following examples illustrate various methods for compositions in the treatment method of the invention. The examples are intended to illustrate, but in no way limit, the scope of the invention.
- Cell sorting: PBMCs were obtained from the peripheral blood of healthy subjects or from cord blood (AllCells) in compliance with institutional IRB protocols. CD4+ T cells were subsequently isolated by negative selection using magnetic beads (Miltenyi Biotech Inc., Auburn, Calif.). Naïve (CD25− CD62L+ CD45RAhi) and central memory (CD25− CD62L⇄ CD45RA−) CD4+ T cells were obtained by staining with the following antibodies: CD62L-FITC, CD4-PerCP, CD45RA-PE-Cy7, CD25-APC-Cy7 (BD Pharmingen, San Diego, Calif.) and were sorted on a FACS Aria (BD Biosciences, Palo Alto, Calif.).
- Differentiation assays: Naïve or central memory CD4+ T cells were stimulated with plate-bound anti-CD3 and soluble CD28 monoclonal antibodies (1 μg/ml, each) in serum-free X-VIVO15 medium (Biowhittaker Inc., Walkersville, Md.) and cytokines (IL-6, 25 ng/ml; TGF-β, 5 ng/ml; IL-1β, 12.5 ng/ml; IL-21, 25 ng/ml; IL-23, 25 ng/ml) for a period of seven days, at which point supernatants were collected and tested by ELISA for IFN-β (BD Biosciences) or IL-17A (eBioscience, San Diego, Calif.) using paired antibodies. Intracytoplasmic staining was performed using standard methodologies and anti-IL-17-APC (R&D Systems, Minneapolis, Minn.) and anti-IFN-β-PE (BD Biosciences) antibodies.
- Real-time PCR: All primers and probes were obtained from Applied Biosystems (Foster City, Calif.), and used according to standard methodologies.
- Antibodies: Antibodies recognizing podoplanin are available commercially from, for example, Abcam Inc. (Cambridge, Mass.) and Santa Cruz Biotechnology, Inc. (Santa Cruz, Calif.). Antibodies to LTB4R1 are available commercially from, for example, Sigma-Aldrich (St. Louis, Mo.) and R&D Systems (Minneapolis, Minn.). The anti-BLT1(LTB4R1):FITC conjugated mAb (202/7B1) was obtained from AbD Serotec (Raleigh, N.C.). See Petersson, et al. (2000) 279 Biochem. Biophys. Res. Commun. 520-25 (2000). The anti-podoplanin antibody used in FACS staining was Rat monoclonal 8F11 obtained from MBL International (Woburn, Mass.). See Watanabe et al., 48 Cancer Res. 6411-16 (1988). The anti-podoplanin antibody used for in vivo injection was designated 8.1.1., obtained from Studies Hybridoma Bank, University of Iowa (Iowa City, Iowa). See Farr et al., J. Histochem. & Cytochem. (1992); Farr et al., J. Exp. Med. (1992).
- Leukotriene B4 (LTB4), a degradation product of arachidonic acid and a potent lipid inflammatory mediator generated rapidly at the site of inflammation, is derived from membrane phospholipids by the sequential actions of cytosolic phospholipase A2 (PLA2), 5-lipoxygenase (5-LO), and LTA4 hydrolase. Jala & Haribabu, 25 Trends Immunol. 315-22 (2004). LTB4 is a potent chemoattractant that triggers the adherence and aggregation of leukocytes to the endothelium and recruits granulocytes and macrophages to the inflammation site. Recent studies have shown that LTB4 may also function as a chemoattractant for T cells. Goodarzi et al., 4 Nat. Immunol. 965-73 (2003); Tager et al., 4 Nature Immunol. 982-90 (2003); Tager & Luster, 69 Prostaglandins, Luekot. Essential Fatty Acids 123-34 (2003); Medoff et al., 202 J. Exp. Med. 97-110 (2005); Miyahara et al., 174 J. Immunol. 4979-85 (2005); Miyahara et al., 172 Am. J. Critical Care Med. 161-70 (2005).
- Gene expression profiling data showed that BLT1 is selectively induced by the combination of IL-6 and TGF-β, which also induces IL-17 (
FIG. 7 ) and leads to the generation of Th17 cells. In order to determine whether the expression of BLT1 could also be observed in human Th17 cells, naïve CD4+ T cells taken from healthy donors and activated with anti-CD3 and anti-CD28 in the presence of a combination of IL-21 and TGF-β, which induces the differentiation of Th17 cells in human cells, were analyzed the surface expression of BLT1 with a BLT1-specific antibody. In the absence of TH17-differentiating cytokines, only 5% of T cells expressed the BLT1 (FIG. 8 ). When human CD4 T cells were differentiated in the presence of IL-21 plus TGF-β, however, some of the CD4+ T cells expressed BLT1. This shows for the first time that that both BLT1 mRNA and protein are rapidly and specifically expressed on mouse and also human Th17 cells. It may be noted that this selective expression on Th17 cells may be restricted to BLT1: the expression of BLT2 was not observed on Th17 cells but was observed on Th2 cells. - Podoplanin (PDP) is another surface molecule identified specifically on Th17 cells. Podoplanin is a transmembrane mucin-containing molecule, which is expressed on the lymphatic endothelium and tumor cells under
pathogenic conditions hematopoetic cells 23. Wicki & Christofori, 2007. This is the first work showing that PDP is expressed on some T cells and more specifically on differentiating Th17 cells (FIG. 10 ). - Importantly, podoplanin constitutes a Th17 specific marker because its expression was not observed in Th1 or Th2 cells (
FIG. 11 ). Therefore, it provides a specific marker to isolate and distinguish Th17 cells with minimal manipulation of T cells. - In addition to Th17 cells, macrophages (CD11b+ cells) from the central nervous system (CNS) of mice with EAE were able to produce IL-17 (
FIG. 12 ). Analysis of the expression of podoplanin on this population revealed that it expressed podoplanin as well. In contrast, microglial cells, did not express significant levels of either IL-17 or podoplanin. Therefore, it appears that podoplanin expression mimics IL-17 expression in both Th17 cells and macrophages, indicating that podoplanin expression can allow the tracking of subsets of pathogenic Th cells (Th17 cells) and also subsets of IL-17-producing pathogenic macrophages. - Leukotriene B4 (LTB4), a degradation product of the arachidonic acid and a potent lipid inflammatory mediator generated rapidly at the site of inflammation, is derived from membrane phospholipids by the sequential actions of cytosolic phospholipase A2 (PLA2), 5-lipoxygenase (5-LO), and LTA4 hydrolase. Jala & Haribabu, 25 Trends Immunol 315-22 (2004). LTB4 is a potent chemoattractant that triggers the adherence and aggregation of leukocytes to the endothelium and recruits granulocytes and macrophages to the inflammation site. Recent studies have shown that LTB4 may also function as a chemoattractant for T cells. Goodarzi et al., 4 Nat. Immunol. 965-73 (2003); Tager et al., 4 Nature Immunol. 982-90 (2003); Tager & Luster, 69 Prostaglandins, Luekot. Essential Fatty Acids 123-34 (2003); Medoff et al., 202 J. Exp. Med. 97-110 (2005); Miyahara et al., 174 J. Immunol. 4979-85 (2005); Miyahara et al., 172 Am. J. Critical Care Med. 161-70 (2005).
- Because LTB4 is involved in the recruitment of different cell types at the site of inflammation, whether the expression of LTB4 could induce the selective migration of Th17 cells was investigated by manipulating its receptor, BLT1. Indeed, LTB4 induced the selective migration of newly differentiated Th17 cells but not Th1 cells (
FIG. 3 ). - More specifically, two G-protein-coupled seven-membrane-domain receptors for LTB4 have been identified and characterized. Tager & Luster, 2003. BLT1 (also called LTBR1) is a high affinity receptor specific for LTB4 and is expressed primarily in leukocytes, whereas BLT2 (LTBR2) is a low affinity receptor expressed more ubiquitously. Id. U-75302, 6-(6-(3R-hydroxy-1E,5Z-undecadien-1-yl)-2-pyridinyl)-1,5S-hexandiol, is a synthetic, specifically binds BLT1. Richards et al., 140 Ann. Rev. Respir. Dis. 1712-16 (1989). U-75302 is available commercially from, e.g., Cayman Chemical (Ann Arbor, Mich.)). Using U75302 as an antagonist of LTB4, it was shown that LTB4 induced a selective migration of Th17 cells, which could be blocked in a dose dependant manner by the addition of different doses of the LTB4 antagonist U-75302 (
FIG. 3 ). - Additionally, the expression of BLT1 on Th17 cells also modulates the function of Th17 cells in vivo, as shown herein. This was determined by testing the effect of BLT1 ablation on the development of experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis, in which Th17 cells have been shown to play an important pathogenic role. To do so, BLT1 knock-out (BLT1 KO) and wild type mice were immunized with myelin oligodendrocyte glycoprotein immunodominant peptide sequence MOG35-55 (encephalitogenic peptide) and injected with pertussis toxin. Mice were maintained according to IACUC protocols. The MOG35-55/pertussis toxin protocol resulted in the development of severe paralysis in wild type animals (
FIG. 4 ). In contrast, BLT1 KO mice immunized with the myelin antigen MOGG35-55 developed less severe diseases compared to the wild type mice, indicating that the lack of BLT1 decreased the development of EAE. In addition, BLT1 (LTB4R1) deficient mice were more resistant to the development of EAE than their wild type littermates. Together, these data indicate that, in addition to tracking Th17 cells selectively, BLT1 expression modulates the functions of Th17 cells in vivo. - Podoplanin was identified as a marker for Th17 cells, and its role in the progression of the animal model of multiple sclerosis, EAE, explored herein. An anti-podoplanin-specific antibody (Farr et al., 176 J. Exp. Med. 1477-82 (1992)), was injected in vivo into mice undergoing EAE. Although mice that received a control antibody developed severe disease and were paralyzed, the mice that received the anti-podoplanin specific antibody did not develop as severe disease, indicating that the anti-podoplanin antibody inhibited the progression of autoimmune disease. Therefore, these data indicate that injection of anti-podoplanin antibody can be used to block the pathogenic activity of Th17 cells and possibly IL-17-producing macrophages and therefore limit the progression of autoimmune diseases, as exemplified here using the animal model of multiple sclerosis, EAE. See
FIG. 5 . - Podoplanin has previously been shown to play an important role in the migration and invasiveness of tumor cells. Wicki & Christophori, 96 Br. J. Cancer, 1-5 (2007). Podoplanin was specifically expressed in Th17 cells and IL-17-producing macrophages. Furthermore, the injection of an anti-podoplanin antibody decreased the severity of EAE. Together, these data indicate that podoplanin can modulate the migration of pathogenic Th17 cells and possibly IL-17-producing macrophages. Determining how podoplanin is involved in the migration of Th17 cells is highly relevant to the treatment of autoimmunity, as the neutralization of podoplanin in an autoimmune setting could prevent further migration of Th17 cells in the CNS during MS attacks and improve relapsing remitting disease.
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/517,116 US9732320B2 (en) | 2008-01-18 | 2014-10-17 | Selective differentiation, identification, and modulation of human TH17 cells |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US654108P | 2008-01-18 | 2008-01-18 | |
US3182408P | 2008-02-27 | 2008-02-27 | |
PCT/US2009/031477 WO2009092087A2 (en) | 2008-01-18 | 2009-01-21 | Selective differentiation, identification, and modulation of human th17 cells |
US86337311A | 2011-06-22 | 2011-06-22 | |
US14/517,116 US9732320B2 (en) | 2008-01-18 | 2014-10-17 | Selective differentiation, identification, and modulation of human TH17 cells |
Related Parent Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/863,373 Division US20110245107A1 (en) | 2008-01-18 | 2009-01-21 | Selective differentiation, identification, amd modulation of human th17 cells |
PCT/US2009/031477 Division WO2009092087A2 (en) | 2008-01-18 | 2009-01-21 | Selective differentiation, identification, and modulation of human th17 cells |
US86337311A Division | 2008-01-18 | 2011-06-22 |
Publications (3)
Publication Number | Publication Date |
---|---|
US20150050732A1 US20150050732A1 (en) | 2015-02-19 |
US20170159016A9 true US20170159016A9 (en) | 2017-06-08 |
US9732320B2 US9732320B2 (en) | 2017-08-15 |
Family
ID=52467110
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/517,116 Expired - Fee Related US9732320B2 (en) | 2008-01-18 | 2014-10-17 | Selective differentiation, identification, and modulation of human TH17 cells |
Country Status (1)
Country | Link |
---|---|
US (1) | US9732320B2 (en) |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7622443B2 (en) | 2002-04-26 | 2009-11-24 | California Institute Of Technology | Method for inhibiting pro-angiogenic activities of endothelial cells selectively at a site of neoangiogenesis in a mammal by administration of the extracellular domain of D1-1 polypeptides |
GB0410103D0 (en) | 2004-05-06 | 2004-06-09 | Biolipox Ab | New method |
US7102003B2 (en) | 2004-07-01 | 2006-09-05 | Bristol-Myers Squibb Company | Pyrrolotriazine compounds |
JP2009543806A (en) | 2006-07-13 | 2009-12-10 | バーナム インスティテュート フォー メディカル リサーチ | Methods and compositions for targeting gC1qR / p32 |
US8906632B2 (en) * | 2007-03-23 | 2014-12-09 | Korea University Research & Business Foundation | Use of inhibitors of leukotriene B4 receptor BLT2 for treating asthma |
US8288357B2 (en) | 2007-03-23 | 2012-10-16 | Korea University Research & Business Foundation | Use of inhibitors of leukotriene B4 receptor BLT2 for treating human cancers |
EP2264182A1 (en) * | 2008-02-28 | 2010-12-22 | Sysmex Corporation | Marker for detection of il-17-producing helper t-cell, and method for detection of il-17-producing helper t-cell |
US20110136113A1 (en) | 2008-08-27 | 2011-06-09 | Sysmex Corporation | Marker for detecting il-17-producing helper t cell, and method for detecting il-17-producing helper t cell |
-
2014
- 2014-10-17 US US14/517,116 patent/US9732320B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US20150050732A1 (en) | 2015-02-19 |
US9732320B2 (en) | 2017-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2238241B1 (en) | Selective differentiation, identification, and modulation of human th17 cells | |
EP3045468B1 (en) | Novel peptides and their use in diagnosis and treatment | |
US20190072568A1 (en) | Diagonsis and treatment of autoimmune diseases by targeting autoimmune-related b cells ("abcs") | |
US20120213768A1 (en) | Diagnostic and Therapeutic Uses for B Cell Maturation Antigen | |
JP6999417B2 (en) | Therapeutic targets and biomarkers in IBD | |
US20220152176A1 (en) | Cancer biomarkers for durable clinical benefit | |
WO2006088890A2 (en) | Treating stroke | |
JP2013517464A (en) | Method for diagnosis and treatment of cutaneous T-cell lymphoma | |
US20240043809A1 (en) | Intestinal organoid co-culture systems and methods for treating or preventing a disease or disorder associated with immune response-mediated tissue injury | |
KR20210004888A (en) | A Cell surface antigen of T cell and the use thereof | |
US9732320B2 (en) | Selective differentiation, identification, and modulation of human TH17 cells | |
US9511086B2 (en) | Method for improving immune system function by administering agents that inhibit DNA-dependent protein kinase-directed apoptosis | |
Arbore et al. | Intrinsic NLRP3 inflammasome activity is critical for normal adaptive immunity via regulation of IFN-γ in CD4+ T cells | |
Moran | Investigation of serum monomeric C-reactive protein and associated auto-antibodies in rheumatoid arthritis | |
Witas | Inactivation of Mer Impairs Efferocytosis and Contributes to an Aberrant Inflammatory Response in a Murine Model of Sjögren’s Syndrome | |
WO2021243177A1 (en) | Markers and cellular antecedents of rheumatoid arthritis flares | |
Ranta | Proprotein Convertase Enzyme Furin as a Biomarker for Immune-Mediated Diseases | |
Ridgley | Cytokine mediated CD4+ T-cell dysregulation in early rheumatoid arthritis | |
US20140235543A1 (en) | Methods for isolating and using a subset of cd8 t-cells that are resistant to inhibitors | |
WO2012116210A2 (en) | Peptide for the induction of immune tolerance as treatment for systemic lupus erythematosus | |
Smith | The Role of CXCL10 in the Pathogenesis of Rheumatoid Arthritis Joint Damage | |
WO2008100217A1 (en) | Polymorphisms in genes of the cryopyrin inflammasome and their uses in the treatment of inflammatory diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: THE BRIGHAM AND WOMEN'S HOSPITAL, INC., MASSACHUSE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KUCHROO, VIJAY K.;ANDERSON, DAVID E.;BETTELLI, ESTELLE;AND OTHERS;SIGNING DATES FROM 20090212 TO 20090304;REEL/FRAME:042025/0632 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
FEPP | Fee payment procedure |
Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
LAPS | Lapse for failure to pay maintenance fees |
Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20210815 |